The role of the Four and a half LIM only protein 2 (FHL2) in bleomycin induced lung fibrosis by Alnajar, A. (Abdulaleem)
  
Biologie 
 
 
The role of the 
Four and a half LIM only protein 2 (FHL2) in 
bleomycin induced lung fibrosis 
 
 
Inaugural-Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften im Fachbereich Biologie 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Westfälischen Wilhelms-Universität Münster 
 
 
 
vorgelegt von 
Abdulaleem Ali Alnajar 
 
 
2013 
  
PhD thesis Abdulaleem Alnajar 
 
 
 
 
 
 
 
 
 
 
 
 
 
------------------------------------------------------------------------- 
Dekanin/Dekan:         Prof. Dr. Dirk Prüfer 
Erster Gutachter:      PD Dr. Viktor Wixler 
Zweiter Gutachter:   Prof. Dr. Martin Bähler 
 
Tag der mündlichen Prüfung(en): 21.06.2013 
Tag der Promotion: 12.07.2013
 I 
PhD thesis Abdulaleem Alnajar 
Incription: 
I woud like to incript my work to the spirit of my father and my mother (the reason of my 
success). Also, I incript my work to my darlings, lovely wife and children. 
 II 
PhD thesis Abdulaleem Alnajar 
Table of contents 
Abstract  .................................................................................................................................................. V 
Zusammenfassung  .................................................................................................................................. VI 
1. Introduction   .........................................................................................................................................1 
1.1. Lung fibrosis  .................................................................................................................................1 
1.1.1. Stages of wonud healing and development of lung fibrosis   ....................................................2 
1.1.1.1. Acute inflammatory stage   ..................................................................................................4 
1.1.1.1.1. Inflammatory cells migration  ..............................................................................................4 
1.1.1.1.2. Mediators of  fibrotic alterations  .........................................................................................8 
1.1.1.2. Fibroblast activation stage   ...............................................................................................13 
1.1.1.3. Matrix remodeling stage  ...................................................................................................14 
1.1.1.3.1. Extracellular matrix proteins  ............................................................................................15 
1.1.1.3.2. Matrix metalloproteinases and their inhibitors  ....................................................................18 
1.1.2. Animal models for lung fibrosis  ...........................................................................................21 
1.2. The LIM-only protein „FHL2”  ...................................................................................................23 
1.2.1. LIM proteins  ........................................................................................................................23 
1.2.2. FHL subtypes   ......................................................................................................................24 
1.2.3. Genetic coding and structure of FHL2  ....................................................................................24 
1.2.4. Expression and cellular localization of FHL2  ..........................................................................25 
1.2.5. Functions of FHL2 and its interaction partners  ........................................................................26 
1.2.6. FHL2 is an important mediator in inflammation, wound healing and fibrosis  .............................27 
1.3. Aim of the Thesis  ........................................................................................................................30 
2. Materials and methods  ........................................................................................................................31 
2.1. Materials  .....................................................................................................................................31 
2.1.1. Chemicals materials  ............................................................................................................31 
2.1.2. Buffer and solutions  ............................................................................................................32 
2.1.3. Animal and histological materials  ........................................................................................35 
2.1.4. Biological materials  .............................................................................................................36 
2.1.4.1. Cell culture materials  ..........................................................................................................36 
2.1.4.2. Primers for RT-PCR  ...........................................................................................................37 
2.1.4.3. Antibodies and enzymes  .....................................................................................................39 
 III 
PhD thesis Abdulaleem Alnajar 
2.1.4.4. Molecular-biological  kits  ...................................................................................................41 
2.1.5. Consumables  .......................................................................................................................42 
2.1.5. Machines, systems and software  ..........................................................................................42 
2.2. Methods  ......................................................................................................................................44 
2.2.1. Animal methods  ..................................................................................................................44 
2.2.1.1. Bleomycin administration  ...................................................................................................44 
2.2.1.2. Depletion of machrophages in vivo   .....................................................................................44 
2.2.1.3. Preparation of bronchoalveolar lavage fluid and lung cells   ....................................................45 
2.2.1.4. Preparation of lung tissue lysates  .........................................................................................46 
2.2.1.5. Isolation of peritoneal murine macrophages  ..........................................................................46 
2.2.2. Tissue culture and cells methods  .........................................................................................47 
2.2.2.1. Tissue cell culture  ..............................................................................................................47 
2.2.2.1.1. General  culturing of eukaryotic cells  ................................................................................47 
2.2.2.1.2. Freezing and thawing of eukaryotic cells  ...........................................................................47 
2.2.2.1.3. Transfection and stimulation of eukaryotic cells  .................................................................48 
2.2.2.2. Flow cytometry assay (FACS analysis)  ................................................................................49 
2.2.3. DNA/RNA methods  .............................................................................................................50 
2.2.3.1. Transformation and isolation of plasmid-DNA from bacteria  .................................................50 
2.2.3.2. Isolation of mRNA from cells or tissue  ................................................................................50 
2.2.3.3. cDNA synthesis  .................................................................................................................51 
2.2.3.4. Real-Time quantitative Polymerase Chain Reaction (qRT-PCR) .............................................52 
2.2.3.5. Gene reporter assay (Luciferase assay)  .................................................................................53 
2.2.4. Protein methods  ..................................................................................................................55 
2.2.4.1. Preparation of protein samples from cells and tissue  ..............................................................55 
2.2.4.2. Determination of protein amounts  ........................................................................................55 
2.2.4.3. Sodium-Dodecyl-Sulfate gel electrophoresis (SDS-PAGE)  ....................................................56 
2.2.5. Immunological methods  ......................................................................................................58 
2.2.5.1. Western blot (immunoblot)  .................................................................................................58 
2.2.5.2. Sircol- assay  ......................................................................................................................59 
2.2.5.3. Immunohistochemistry (IHC)  ..............................................................................................59 
2.2.6. Histological methods  ...........................................................................................................61 
2.2.6.1. Fixation and embedding in paraffin of lung tissue samples .....................................................61 
 IV 
PhD thesis Abdulaleem Alnajar 
2.2.6.2. Haematoxylin and Eosin (HE) & Trichrome staining  ............................................................. 61 
2.2.6.3. Continuous numerical scale system  ......................................................................................62 
2.2.7. Data analysis  .......................................................................................................................63 
3. Results and discussion  .........................................................................................................................64 
3.1. Sensitivity of WT and FHL2KO mice to BLM treatment  ............................................................64 
3.2. Development of BLM-induced lung fibrosis  ................................................................................65 
3.3. Expression of ECM proteins during BLM-induced lung fibrosis  .................................................68 
3.4. FHL2 inhibits expression of tenascin C  .......................................................................................69 
3.5. FHL2-deficient mice have a higher inflammation status in lungs  .................................................71 
3.6. Immune status of bleomycin-treated lungs   .................................................................................75 
3.7. Macrophages activation during BLM-induce lung fibrosis  ..........................................................78 
3.8. FHL2 deficiency abrogates DC-SIGN-mediated activation of macrophages  ................................79 
3.9. FHL2 enhance macrophages MMP-12 expression  .......................................................................81 
3.10. Macrophage depletion aggravates lung fibrosis   ........................................................................83 
4. References  ..........................................................................................................................................87 
5. Appendix  ............................................................................................................................................97 
5.1. List of Figures  ….. ................................................................................................... ……………..97 
5.2. List of Tables   ..............................................................................................................................98 
5.3. List of Symbols  ............................................................................................................................99 
Acknowledgement   .............................................................................................................................. 102 
CURRICULUM VITAE  ...................................................................................................................... 103 
 
 
 
 
 
 
 
 V 
PhD thesis Abdulaleem Alnajar 
Abstract 
Pulmonary fibrosis is a progressive fibrotic disease which takes place when regenerative 
processes have failed or long-term inflammation occurs. It is characterized by activation of 
tissue fibroblasts and deregulated synthesis of extracellular matrix proteins. It causes scarring 
of alveolar compartments of the lung where gas exchange occurs and results in tissue damage. 
While fibrotic alterations may be induced by variety of causes, available data increasingly 
indicate that chronic inflammation and aberrant wound healing play an important role in the 
development of the disease. Bleomycin (BLM) is a chemotherapeutical drug with a serious 
side effect. Namely, it induces lung fibrosis. BLM causes alveolar cell damage by 
intercalating into DNA and by inducing lipid peroxidation. Today it is one of the best 
established animal models of lung fibrosis. 
FHL2 (four-and-a-half LIM domain protein 2) is a scaffolding protein which is able to 
interact with numerous cellular proteins regulating signaling cascades and gene transcription. 
It is involved in tissue remodeling and tumor progression and existing data suggest that FHL2 
might supports fibrogenesis by maintaining the transcriptional expression of αSMA and 
excessed synthesis and assembly of matrix proteins in activated fibroblasts. Therefore we 
hypothesized that FHL2 is a protein that supports fibrogenesis. 
To study the role of FHL2 in development of fibrosis, we chose the bleomycin-mediated lung 
fibrosis model and studied the development of the disease in WT mice in comparison with 
FHL2 knockout animals. Contrary to our expectation, FHL2-deficient mice developed more 
severe lung pathology after application of BLM than WT mice. Our histological, tissue cell 
culture and molecular cell biology studies showed that FHL2 does not aggravate the 
bleomycin-induced lung fibrosis but rather restrained it by attenuating lung inflammation. We 
showed that FHL2 inhibits the transcription of the pro-inflammatory matrix protein tenascin C 
and simultaneously stimulates the expression of the macrophage activating C-type lectin 
receptor DC-SIGN. Consequently, upon bleomycin application FHL2 knockout mice 
developed a severe and long-lasting lung inflammation due to enhanced expression of 
tenascin C and impaired accumulation of activated and inflammation ceasing macrophages. 
Finally, the particular importance of macrophages in restricting fibrotic alterations was 
proofed by in vivo depletion of lung macrophages during development of BLM-induced lung 
fibrosis. 
 
 VI 
PhD thesis Abdulaleem Alnajar 
Zusammenfassung 
Die Lungenfibrose geht mit einer Transformation von Lungenfibroblasten zu Myofibroblasten 
und einer Überexpression und Ablagerung von extrazellulären Matrixproteinen einher. Die 
verstärkte Bildung von Bindegewebe führt letztendlich zu zunehmenden Gewebsschäden und 
einer stark eingeschränkten Lungenfunktion. Die Lungenfibrose ist eine sich progressiv 
entwickelnde Erkrankung, wenn Gewebsregenerationen fehlgeschlagen oder langanhaltende 
Entzündungen überhandgenommen haben. 
Bleomyzin (BLM) ist ein Antibiotikum, das in der Tumortherapie eingesetzt wird. Es hat 
jedoch einen starken Nebeneffekt, die Entwicklung der Lungenfibrose. BLM interkaliert in 
die DNA und induziert zusätzlich Oxidation von Lipiden, was zu verstärkten Gewebsschäden 
führt. Auch in Nagern kann eine Lungenfibrose durch Applikation von BLM hervorgerufen 
werden und ist heutzutage das bestuntersuchte Tiermodel zur Lungenfibrose.  
FHL2 (Viereinhalb-LIM-Domänen Protein 2) ist ein Adapterprotein, das mit mehreren 
zellulären Proteinen wechselwirkt und als solches mehrere Signalübertragungskaskaden und 
Gentranskriptionen reguliert. Es ist in Gewebeumbauprozesse und Tumorprogression 
involviert. Des Weiteren wurde gezeigt, dass FHL2 als Kofaktor der Transkription die 
Expression von aSMA und als integrinbindendes Protein die Assemblierung von 
extrazellulären Matrixproteinen fördert. Daher sollte in dieser Arbeit geprüft werden ob und 
inwieweit das FHL2 Protein die Entwicklung der Lungenfibrose begünstigt. 
Um dieser Fragestellung nachzugehen, wurde die Entwicklung der Bleomyzin-induzierten 
Lungenfibrose in FHL2 Wiltyp und Knockout Mäusen verglichen. Erstaunlicherweise zeigten 
FHL2-defiziente Tiere einen schwereren Krankheitsverlauf als Wildtyp Mäuse. Histologische, 
zellkulturische sowie molekularbiologische Studien zeigten jedoch, dass die Abwesenheit von 
FHL2 per se nicht zu einer Steigerung der Fibrosierung des Lungengewebes führt, sondern 
eine verstärkte inflammatorische Reaktion in der Lunge hervorruft. Die Entzündung des 
Lungengewebes in FHL2 Knockout Mäusen nach BLM Induktion ist im Vergleich zu 
Wildtyp Tieren nicht erhöht, sondern entwickelt sich wesentlich früher und flammt langsamer 
ab als in Wildtyp Mäusen. Es konnte gezeigt werden, dass dies auf zwei wichtigen 
Funktionen des FHL2 Proteins beruht, die in der Knockout Maus fehlen. Zum einen hemmt 
FHL2 als Kofaktor der Transkription die Expression des entzündlichen Proteins Tenascin C. 
Zum anderen, ist FHL2 essentiell für die Expression von DC-SIGN, des C-Typ 
Lektinrezeptors der Makrophagen, nach deren Stimulation mit kohlehydratreichen 
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Gewebslysaten. Dementsprechend wurde in FHL2 Knockout Lungen nach BLM Applikation 
das Tenascin C verstärkt exprimiert und die residenten Makrophagen unzulängluich aktiviert, 
was zu einer erhöhten und langanhaltenden Entzündung führt.  
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1. Introduction  
1.1. Lung fibrosis 
The primary function of the lung is to provide a sufficient size and highly efficient area for 
gas exchange (Robert et al. 2010; Nkyimbeng Takwi 2008). The lung has two well defined 
interstitial connective tissue compartments arranged in series: the parenchymal interstitium 
and the loose connective tissue (peribronchovascular sheaths, interlobular septa and visceral 
pleura). The parenchymal interstitium of the alveolar wall makes up about 33% of the total 
interstitial volume (Figure 1) (Nkyimbeng Takwi 2008; Robert et al. 2010). 
 
Figure 1: Schematic view of the lung parenchyma that surrounds an alveolar space showing the major cells that 
line and lie within the putative interstitial space (Nkyimbeng Takwi 2008; Robert et al. 2010). 
 
Fibrosis usually takes place when regenerative processes have failed and /or long- term 
inflammation occurs after tissue damage. It is characterized by activation of fibroblasts which 
leads to excess deposition of extracellular matrix (ECM) components (Krieg et al. 2007; 
Wynn 2011; Wynn 2007; Pottier et al. 2007). Tissue damage may result from various stimuli, 
including infections, autoimmune reactions, toxins, radiation and drugs or chemical insults 
(such as bleomycin, gentamicin and cisplatin) (Wynn 2008; Nuno 1998; Pinart et al. 2008; 
Mouratis &Aidinis 2011; Pottier et al. 2007). 
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The lung fibrosis is an acute&chronic inflammatory disease, which results in scarring of the 
alveolar compartment of the lung where gas exchange occurs (William et al. 2007; Herbert 
2005; Robert et al. 2011; Wynn 2011). Fibrosis can also involve other areas of the lung, such 
as bronchi and pleura, but in general the unqualified term pulmonary fibrosis usually indicates 
alveolar pathology of the lung (Jantz & Antony 2006; William et al. 2007; Wick et al. 2009). 
The lung fibrosis corresponds to the end stage of lung injury. The progression of this disease 
results in the widening of interstitial matrix, eventual compression and destruction of normal 
lung parenchyma, with damage of capillaries. These factors are related to the extent of tissue 
scarring (Razzaque & Taguchi 2003; Wynn 2011). The scar formation ultimately leads to 
organ malfunction, disruption of gas exchange, and death from respiratory failure (Wynn 
2011; Raghu et al. 2006). 
Idiopathic pulmonary fibrosis (IPF) is one of the most common forms of lung fibrosis. It is 
diagnosed in 34,000 new patients per year in the United States (Raghu et al. 2006) and is 
often a severely debilitating and fatal condition; the median survival of patients with IPF is 
approximately 3 years from the time of diagnosis (Irina et al. 2008; Daniil et al. 1999). 
1.1.1. Stages of wound healing and development of lung fibrosis: 
Fibrogenesis is often defined as an out of control wound healing response (Mutsaers et al. 
1997). The development of wound repair and lung fibrosis has three distinct stages: i) the 
acute inflammatory stage (includes migration of inflammatory cells into the wounded area 
and secretion of inflammatory mediators), ii) the stage of active fibroblast migration and 
proliferation and a iii) the tissue remodeling stage (Figure 2) (Razzaque & Taguchi 2003; 
Wynn 2011; Wick et al. 2009; Robert et al. 2011; Mutsaers et al. 1997; Rajendra 1994).  
After lung tissue injury, epithelial cells release large amounts of bioactive lipids and 
inflammatory mediators that initiate an antifibrinolytic coagulation cascade, which triggers 
platelet activation and blood clot formation (Annie & Moises 2002; Wynn 2011; Wynn 2008). 
This is followed by migration of leukocytes (e.g., neutrophils, macrophages, and T- cells) into 
the site of injury. Neutrophils are the most abundant inflammatory cell at the earliest stages of 
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wound healing, but are quickly replaced by macrophages after neutrophil degranulation 
(Shaw et al. 2009; Wynn 2011; Wynn 2008; Martin 2009). The activated macrophages and 
neutrophils remove dead cells and eliminate invading microrganisms (Shaw et al. 2009; 
Wynn 2011). The recruited leukocytes secrete profibrotic cytokines such as tumor necrosis 
factor (TNF), interleukin-1 (IL-1), interleukin-13 (IL-13), transforming growth factor (TGF-
β) and different ELR+ motif (Glu-Leu-Arg domain) containing CXC chemokines (Wick et al. 
2009; Robert et al. 2011; Wynn 2011; Jack et al. 1993). Also, the macrophages secrete matrix 
metalloproteinases (MMPs), e.g. MMP-12, which largely regulate the inflammatory cytokine 
and chemokine secretion and migration of cells into the site of inflammation (Dean et al. 
2008). 
In the subsequent phase, fibrocytes from the bone marrow and resident fibroblasts proliferate 
and differentiate into myofibroblasts, which release ECM components (Wynn 2011; Wick et 
al. 2009; Robert et al. 2011). Fibroblasts and myofibroblasts may also be derived from 
epithelial cells undergoing epithelial/endothelial-mesenchymal transition (EMT) (Hinz et al. 
2007; Wynn 2011). In the final remodeling and resolution phase, activated myofibroblasts can 
promote wound repair by regulating wound contraction and restoration of blood vessels 
(Wynn 2011; Mutsaers et al. 1997). However, fibrosis often develops if any stage in the tissue 
repair program is dysregulated or when the lung-damaging stimulus persists (Wynn 2011; 
Annie & Moises 2002; Rajendra 1994). The stages of wound healing and development of 
lung fibrosis are described in more detailes in sections below. 
Figure 2: Disruptions in normal wound healing contribute to the development of lung fibrosis (Wynn 2011). 
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1.1.1.1. Acute inflammatory stage: 
The alveolar surface of the lung is lined by type 1 and type 2 epithelial cells. Type 1 cells, 
which cover more than 90% of the alveolar surface area of the peripheral lung, are highly 
attenuated cells that interface with pulmonary capillaries (see Figure 1) (Moises and Annie 
2006; Wynn 2011). The geometry of these cells is ideally suited for gas exchange (Annie & 
Moises 2002).  
The damage of epithelial cells and/ or endothelial cells as result of tissue injury plays an 
important role in fibrogenesis (Kisseleva & Brenner 2008; Wynn 2011). These cells secrete 
numerous inflammatory mediators, including, transforming growth factor (TGF-β1), platelet-
derived growth factor (PDGF), tumor necrosis factor-alpha (TNF-α), interleukins, members of 
ELR+ motif (Glu-Leu-Arg domain) containing CXC chemokines and members of the 
fibroblast growth factor family (FGF) (Strieter et al. 2007; Kisseleva & Brenner 2008). These 
inflammatory mediators induce platelet aggregation and degranulation, blood clot formation 
and are responsible for active recruitment of inflammatory cells and for accumulation of 
provisional ECM (Strieter et al. 2007; Kisseleva & Brenner 2008; Wynn 2011). 
Platelet aggregation and their subsequent degranulation in turn promotes blood vessel dilation 
and increased permeability, allowing efficient recruitment of inflammatory cells (e.g., 
granulocyte neutrophils, macrophages, and lymphocytes) to the site of injury (Wynn 2011; 
Wick et al. 2009; Robert et al. 2011; Rajendra 1994; Kisseleva & Brenner 2008).  
1.1.1.1.1. Inflammatory cell migration stage 
Migration of inflammatory cells to the site of the acute injury is a part of wound healing 
(Kisseleva & Brenner 2008; Pinart et al. 2008; Wick et al. 2009). The cellular components of 
the immune system appear at the site of injury in a specific sequence and time frame as shown 
in Figures 2 and 3 (Wynn 2011; Martin 2009). 
Neutrophils are the first immune cells that arrive at the site of injury within minutes (the time 
frame for the highest activity lies between the first 3 to 24 h) (Shaw et al. 2009; Kisseleva & 
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Brenner 2008). Following neutrophils, the macrophages migrate to the site of tissue injury 
within 24-48 h and become the predominant immune cell type (Martin 2009; Timothy et al. 
2006; Wick et al. 2009). T- and B- lymphocytes are also recruited to the site of injury, 
although to some what later time points, and further facilitate secretion of fibrogenic 
cytokines (Kisseleva & Brenner 2008). The pro-inflammatory-fibrotic factors which have 
been secreted by the inflammatory cells regulate the migration and proliferation of fibroblasts 
(Wynn 2011; Kisseleva & Brenner 2008).  
 
Figure 3: Immune cell content of the healing wound. The cellular components of the immune system in the 
wound in a specific sequence and time frame (Martin 2009). 
 
- Neutrophils 
Neutrophils are polymorphonuclear leukocytes, which play a central role in innate immunity 
by phagocytosing and destructing invading microorganisms through production of reactive 
oxygen intermediates and releasing proteolytic enzymes (Timothy et al. 2006; Driss & Janos 
2010). During wound healing and development of lung fibrosis, neutrophils are one of the 
first-responders of inflammatory cells that migrate towards the site of inflammation. They 
migrate through the blood vessels, then through interstitial tissue (Shaw et al. 2009; Wynn 
2011; Kisseleva & Brenner 2008).  They also produce a variety of cytokines and chemokines 
that amplify the inflammatory response and trigger fibroblast proliferation and recruitment 
(Timothy et al. 2006; Wynn 2011; Razzaque & Taguchi 2003). 
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-Macrophages  
Macrophages (MΦ) are phagocytic cells derived from monocytes (Nishida & Hamaoka 2008). 
They express a number of specific surface proteins, including F4/80 in case of mice, and can 
be identified by flow cytometry or immunohistochemical staining (Khazen et al. 2005). It has 
been shown that macrophages can be activated by lipopolysaccharide (LPS), a component of 
the gram negative bacterial cell wall (Fanying and Clifford 1997). 
Activated macrophages release chemokines (such as CCL2 and CCL3), cytokines (such as 
tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-13 (IL-13), 
macrophage inflammatory protein-1 (MIP-1) and reactive oxygen species (ROS) (Smith et al. 
1994; Robert et al. 2011; Wynn 2011).  
Lung macrophages are integrated into all stages of wound healing and fibrosis and they role 
in regulation of these processes is multifunctional but very essential (Wynn and Barron, 2010; 
Herbert 2005). The macrophages phagocytose cell debris, induce apoptosis, recruit 
inflammatory cells and myofibroblasts and regulate vascularization, but they are also involved 
in induction of scar formation (Nishida & Hamaoka 2008; Timothy et al. 2006). Lung 
macrophages terminate and resolve the lung inflammation and fibrosis by secreting mediators 
that induce myofibroblast apoptosis, by removing cellular debris that can drive inflammation, 
by clearance of alveolar edema fluid, by regulation of angiogensis and 
proliferation/differentiation of epithelial cells to repair the damage, by digesting and engulfing 
ECM components, and by stimulating the production of matrix metalloproteinases (MMPs) 
(Wynn and Barron 2010; Nishida & Hamaoka 2008; Wynn 2011; Herold et al. 2011). From 
MMPs secreted by macrophages the MMP-12 plays an essential important role. It does not 
only degrade extracellular matrix proteins but also regulate the recruitment of inflammatory 
cells to sites of tissue injury as well as cytokine and chemokine secretion (Zuo et al. 2002; 
Nishida & Hamaoka 2008; Dean et al. 2008; Iredale et al. 1998). The macrophage-specific 
metalloelastase (MMP-12) inactivates different ELR+ CXC- and CC chemokines, which 
underscores the absolute essential role of macrophage in terminating polymorphonuclear 
leukocyte influx during inflammation (Dean et al. 2008). Macrophages can be selectively 
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depleted from tissues in vivo by using clodronate containing liposomes, allowing 
investigating the role of these cells in fibrotic processes (Rooijen and Sanders 1994). 
Macrophage depletion during the recovery phase of renal fibrosis led to a failure of matrix 
degradation and persistent scarring (Nishida & Hamaoka 2008). In myocardial wound 
healing, macrophage depletion impaired wound healing (Van Amerongen et al. 2007). Other 
studies show that injection of macrophages into healing cutaneous wounds augments the 
repair process (David et al. 1989). 
 
-Lymphocytes: 
Lymphocytes are a type of leukocytes in vertebrate immune system (Charles et al. 2001). 
Under the microscope, lymphocytes can be divided into large and small lymphocytes. Large 
granular lymphocytes include natural killer cells (NK cells). Small lymphocytes consist of T- 
cells (thymus cells) and B cells (bursa-derived cells) (Charles et al. 2001). The basis for 
lymphocyte immune function is the highly selective clonal expansion of individual 
lymphocytes following exposure to specific antigens (Charles et al. 2001). Lymphocytes, 
together with monocyte-derived macrophages, are common participants in inflammatory 
responses associated with various forms of tissue injury (Russel 1994). 
T- cells have an immportent role during wound healing and development of fibrosis. In the 
wound, the active hypertrophic scar tissue was infiltrated with T- cells, and also they are 
characteristic for the remission phase of hypertrophic scar formation (Boyce et al. 2000; 
Bernabei et al. 1999). 
Infiltration of T- lymphocytes into the lung is common in patients with lung fibrosis and in 
animal models for this disease as well. These cells have a role in regulating the accumulation 
of extracellular matrix and modulation of the inflammatory and healing responses in the lung 
and they may work in a profibrotic or an antifibrotic (Naohito et al. 1996; Wynn 2011; Irina et 
al. 2008). Activated T- lymphocytes may produce proinflammatory mediators such as IFNγ, 
TNFα, Il-4 or Il-13 as part of the overall inflammatory pattern (Atamas et al. 2003). Also, T 
cells regulate fibroblast proliferation and apoptosis and differentiation of other cells such as 
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macrophages during wound healing or lung fibrosis development (Atamas et al. 2003, 
Naohito et al. 1996). 
B-cells can play important roles in the pathogenesis of various autoimmune diseases, e.g. 
rheumatic arthritis, either by secretion of auto-antibodies or production of proinflammatory 
cytokines or auto-antigen presentation (Hogan et al. 2010). B-cells can produce a wide 
spectrum of cytokines under inflammatory conditions, including IL-4, IL-6, TGF-β and IFN-γ 
(Hogan et al. 2010). B-cells may also play a regulatory role by modulating the production of 
IL-10; an anti-inflammatory cytokine which can suppres harmful immune responses resulting 
in the prevention of innate cell mediated inflammatory responses (Mauri et al. 2003; Hogan et 
al. 2010). The depletion of B- cells in the tight-skin mouse model for systemic sclerosis 
results in reducing of skin fibrosis and autoimmunity (Hasegawa et al. 2006). 
 
1.1.1.1.2. Mediators of fibrotic alterations 
- Cytokines and chemokines: 
During development of wound healing and lung fibrosis, inflammatory reactions in the lung 
are orchestrated by inflammatory and stationary cells as well as inflammatory cytokines and 
chemokines secreted by them (Commins et al. 2010; Wick et al. 2009; Robert et al. 2011). 
Cytokines are small secreted cell-signalling proteins with paracrine, autocrine and even 
endocrine functions (Commins et al. 2010). Chemokines are an important subgroup of 
cytokines (Commins et al. 2010). Cytokines and chemokines are essential mediators of 
inflammation and immunity during development of lung fibrosis (Chung 2001; Wynn 2011; 
Wick et al. 2009; Robert et al. 2011; Jack et al. 1993). 
Tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-13 
(IL-13) are proinflammatory cytokines, that promote inflammation by activating a variety of 
inflammatory mediators that are crucial in the cascade of events leading to tissue 
inflammation (Borish and Steinke 2003; Chung 2001). These cytokines promote the matrix 
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metalloproteinase (MMP) secretion and the proliferation of fibroblasts. They are mostly 
secreted by macrophages (Wynn 2011; Borish and Steinke 2003; Chung 2001).  
TNF-α is an important mediator of innate immunity. It has direct cytotoxic effects and 
induces further immune responses (Chung 2001). TNF-α stimulates the expression of other 
proinflammatory mediators, leukocyte adhesion factors, and CCL (CC chemokine ligand) 
(Wynn 2011; Chung 2001). Furthermore, TNF-α enhances resolution of inflammation by 
promoting of apoptosis of neutrophils (Emmet et al. 2011; Kettritz et al. 2000). TNF-α 
inhibitors are mainly used in the treatment of rheumatoid arthritis and other auto-immune 
diseases (Feldmann & Maini 2003; Meyer 2008). Further, TNFα increases MMPs synthesis in 
myofibroblasts regulating thus matrix proteins degradation, such as collagen, during fibrosis 
(Debra et al. 1996).  
IL-1 is an important cytokine involved in acute and chronic inflammation, and it is involved 
in various disorders of the lung (Kolb et al. 2001). IL-1 induces the activation of ROS-
expressing neutrophils, which can further damage epithelial cells (Wynn 2011; Kolb et al. 
2001). IL-1 also promotes production of TGF-β, a major profibrotic cytokine and activator of 
myofibroblasts (Krieg et al. 2007; Wynn 2011). TGF-β induces the expression of SMA 
(alpha smooth muscle actin), which is incorporated into -actin microfilaments and confers 
high contractile properties to myofibroblasts (Hinz et al. 2007). IL-6 is an important 
pleiotropic cytokine with both pro- and anti-inflammatory properties including a wide range 
of biological activities in immune regulation, hematopoiesis and inflammation (Chi-Hang et 
al. 2012; Papanicolaou et al. 1998). Many studies have shown that induction of IL-6 requires 
activation of the NF-kB which is often involved in immune and inflammatory responses (Beg 
et al. 1996; Papanicolaou et al. 1998; Chi-Hang et al. 2012). In rheumatoid arthritis (RA), IL-
6 inhibits the proliferation of fibroblastic synovial cells (Norihiro et al. 2000). Furthermore, 
IL-6 plays an important role in the development of bleomycin-induced lung inflammation and 
fibrosis, possibly through up-regulation of CCL3 and TGFβ (Fumitake et al. 2008). 
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Chemokines have been classified into 4 subfamilies, based on the presence of cysteins at the 
amino terminal part: CXC (α-chemokines) and CC (β-chemokines), CX3C and C (Commins 
et al. 2010; Wynn 2008). Among chemokine subfamilies, CXC chemokines can be further 
subclassified into Glu-Leu-Arg (ELR) + and ELR− CXC chemokines, based on the presence 
or absence of a tripeptide motif ELR at the NH2 terminus. Characteristic of ELR+ 
chemokines is their ability to specifically recruit neutrophil polymorphonuclear leucocytes 
(PMN) into inflamed tissues (Cinzia et al 2006). 
Several CC chemokines are produced by activated macrophages and other inflammatory cells 
which regulate fibrogenesis by controlling myofibroblast recruitment (Wynn 2008; Strieter et 
al. 2007). CCL3 (macrophage inflammatory protein 1α) and CCL2 (monocyte 
chemoattractant protein-1), are chemotactic for mononuclear phagocytes, they were identified 
as profibrotic mediators (Wynn 2008). Macrophages and epithelial cells are believed to be the 
key sources of CCL3 (Smith et al. 1994). Studies in the bleomycin model of pulmonary 
fibrosis showed that anti-CCL3 antibodies could significantly reduce the development of 
fibrosis (Smith et al. 1994; Smith et al. 1995). 
 
-S100A8/A9 
S100 proteins compose a family of low molecular weight Ca-binding proteins found in 
vertebrates (Zimmer et al. 1995; Foell et al. 2004). The name S100 is derived from the fact 
that these proteins are 100% soluble in ammonium sulfate at normal pH (Zimmer et al. 1995; 
Foell et al. 2004). The S100 proteins were firstly identified by Moore in 1965 (Foell et al. 
2004). They regulate the cytoskeletal metabolism and the oxidant & antioxidant balance 
(Bargagli et al. 2011). S100 proteins belong to the alarmin family, which are endogenous 
molecules found at high levels during inflammatory conditions and at sites of inflammation 
(Chan et al. 2012). S100 proteins are biomarkers for inflammatory disorders, but also act as 
pro-inflammatory proteins by activating immune and endothelial cells (Bargagli et al. 2011; 
Foell et al. 2004). 
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S100A8 and S100A9 are highly expressed by neutrophils, monocytes and activated 
endothelial and epithelial cells (Ryckman et al. 2003; Bargagli et al. 2011). The “alarmins“ 
S100A8/A9 have different roles during inflammation. They modulate the pro-inflammatory 
response by regulating neutrophil adhesion and migration (Chan et al. 2012) but also may as 
ligands for TLR4 receptor stimulate activation of immune cells (Vogl et al 2007; Nature 
Medicine). S100A9, also known as calgranulin B, is overexpressed in breast, lung and 
colorectal cancer cells and in target tisues of many autoimmune inflammatory diseases such 
as rheumatoid arthritis, juvenile idiopathic arthritis, chronic inflammatory bowel disorder and 
myositis (Bargagli et al. 2011; Gebhardt et al. 2006). S100A9 has also been associated with 
the pathogenesis of chronic and acute lung diseases such as cystic fibrosis, chronic obstructive 
pulmonary disease (COPD), and Acute Respiratory Distress Syndrome (ARDS) (Foell et al. 
2004; Bargagli et al. 2011; Lorenz et al. 2008).  
 
-DC-SIGN (CD209) 
DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) 
also known as CD209 (Cluster of Differentiation 209) is a protein which is encoded by the 
CD209 gene in humans (Curtis et al. 1992). CD209 (DC-SIGN) is a C-type lectin receptor 
present on both macrophages and dendritic cells (Soilleux et al. 2002). DC-SIGN on 
macrophages binds to mannose type carbohydrates, a class of pathogen associated molecular 
patterns (PAMPs) commonly found on viruses, bacteria and fungi. This binding activates 
phagocytosis (McGreal et al. 2006; Cambi and Figdor 2003; McGreal et al. 2005; Kerrigan & 
Brown 2009). DC-SIGN has also an important role in adhesion and migration of macrophages 
and dendritic cells during inflammation (McGreal et al. 2005; Cambi and Figdor 2003). 
Forthermore, DC-SIGN plays an important role in inflammatory response, proliferation and 
initiating of the immune response (Zhou et al. 2006; van den Berg et al. 2012). The 
intracellular signaling pathway induced by this C-type lectin modulates the response of other 
pattern recognition receptors (PRRs), such as TLRs. DC-SIGN activates the serine/threonine 
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protein kinase RAF1 and there by induces phosphorylation of the  NF-kB subunit p65 at 
serine residue 276 (Figure 4) (van den Berg et al. 2012). This signaling pathway leads to the 
expression of specific cytokines, such as IL-6, which have a role in regulation of immune 
responses (van den Berg et al. 2012; Zhou et al. 2006). 
                                   
Figure 4: DC-SIGN signaling modulates TLR signaling. DC-SIGN binds ligands such as mycobacteria and 
HIV-1. DC-SIGN induces RAF1 phosphorylation, which modulates TLR induced NF-κB activation. Upon TLR 
stimulation the canonical NF-kB subunit p65 is released from its inhibitor and translocates to the nucleus. 
Phosphorylated RAF1 induces p65 phosphorylation at Ser276 that functions as a binding site for the histone 
acetylase CBP. Acetylation of p65 induces enhanced and prolonged Il6, Il10 and Il12ab transcription (van den 
Berg et al. 2012). 
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1.1.1.2. Fibroblast activation stage: 
Fibroblast migration, proliferation and activation is stimulated by different inflammatory 
cytokines, chemokines and growth factors which are secreted by inflammatory cells during 
development of wound healing and lung fibrosis (Kisseleva & Brenner 2008; Wynn 2011). In 
the “second” stage of wound healing fibroblasts become activated and converted into 
myofibroblasts that synthesize and secrete ECM components (Wynn 2011; Kisseleva & 
Brenner 2008). Myofibroblasts possess ultrastructural features that are intermediate between 
fibroblasts and smooth muscle cells; they are characterized by high expression of alpha-
smooth muscle actin (aSMA) (Hinz et al. 2007; Hinz 2007; Kisseleva & Brenner 2008).  
Myofibroblasts are generated during a processes termed epithelial/endothelial-mesenchymal 
(EMT/EndMT) transition from a variety of sources including resident mesenchymal cells, 
epithelial and endothelial cells as well as from circulating fibroblast-like cells called 
fibrocytes that in turn are derived from bone-marrow (stem cells) (Hinz et al. 2007; Krieg et 
al. 2007). Fibroblasts and myofibroblasts are the cells responsible for the synthesis and 
secretion of extracellular matrix proteins that are at the core of the fibrotic transformation of 
the lung (Hinz 2007; Wynn 2011). Myofibroblast interacts with ECM via integrin receptors. 
This interaction is an important factor for understanding complex events in fibrosis (Eckes et 
al. 2000). 
Myofibroblasts are activated by several growth factors and cytokines. Being activated 
myofibroblasts synthesize and secrete high amounts of ECM components, including 
fibronectin, tenascins, collagens as well as matrix metalloproteinases (MMPs) and their 
inhibitors (Krieg et al. 2007; Wynn 2011). During fibrosis the proliferation of myofibroblasts 
as well as synthesis of collagens and tissue inhibitors of MMPs (TIMPs) are increased, while 
myofibroblast apoptosis and MMPs-collagenase expression are decreased (Schuppan et al. 
2001). Moreover, myofibroblasts have additional function in ECM contraction, through 
formation of stress fibers containing smooth muscle actin; myofibroblasts can exert 
substantial remodeling forces on the granulation tissue (Wynn 2007; Hinz 2007).  
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1.1.1.3. Matrix remodeling stage: 
Tissue remodeling is the final stage of wound healing and lung fibrosis development, in this 
stage, myofibroblasts promote wound contraction, a process where the edges of the wound 
migrate toward the center and epithelial/endothelial cells divide and migrate over the 
temporary matrix to regenerate the damaged tissue (Wynn 2011; Rajendra 1994; William et 
al. 2007). Fibrosis develops when the wound is severe, the tissue-damaging irritant persists, or 
when the repair process becomes dysregulated. Thus, many stages in the wound repair 
process can run abnormal and contribute to scar formation (Razzaque & Taguchi 2003; Wynn 
2011). The balance between matrix formation and degradation is disrupted in fibrotic 
diseases, usually due to the increased production and decreased degradation of extracellular 
matrix proteins (Razzaque & Taguchi 2003). 
The extracellular matrix (ECM) is a complex structural entity surrounding and supporting 
cells that are found within mammalian tissues (Steven et al. 1997). There are two main forms 
of ECM; interstitial matrix and basement membrane or basal lamina. Both of them are 
composed of aggregates of matrix proteins (Murray 2010; Korpos et al. 2010; Steven et al. 
1997). The interstitial matrix forms the majority of the connective tissue between cells and 
acts as scaffold for migrating cells. Basement membranes form sheet-like matrix barriers that 
separate epithelial cells from underlying mesenchymal cells (Korpos et al. 2010; Murray 
2010). 
Generally, ECM regulates different cellular functions, such as cell proliferation and 
differentiation, migration, adhesion, cell metabolism and gene expression. It regulates these 
functions through signaling via cellular adhesion receptors. Besides this, ECM is also a 
reservoir for extracellular signaling molecules such as cytokines and growth factors (Rajendra 
1994; Steven et al. 1997). Figure 5 shows cell-ECM interactions and that binding of matrix 
molecules to cell receptors initiates’ different cell signaling mechanisms (Steven et al. 1997). 
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Figure 5: ECM-cell and cell-cell interactions (Steven et al. 1997).  
The generation of ECM is predominantly achieved through the production of collagenous and 
non-collagenous proteins (e.g. fibronectin, laminin and tenacin c), whereas degradation of 
ECM is predominantly achieved by various proteolytic enzymes, such as matrix 
metalloproteinases (MMP) (Wynn 2008; Razzaque & Taguchi 2003). In addition, tissue 
inhibitors of metalloproteinases (TIMPs) also play an active role in matrix remodeling by 
neutralizing MMP activities (Wynn 2008). These proteins and enzymes are described in more 
details in following section. 
 
1.1.1.3.1. Extracellular matrix proteins 
The matrix proteins play an essential role in tissue injury remodeling and failure in synthesis 
of these proteins or their deposition might result in fibrosis (Wynn 2011; Rajendra 1994; 
William et al. 2007). During inflammation, the extracellular matrix (ECM) acts as a scaffold 
for cell infiltration and as a reservoir for cytokines and growth factors (Steven et al. 1997). 
ECM compounds such as fibronectin or vitronectin have tri- peptide cell binding sites, Arg-
Gly-Asp (RGD), to which integrins bind and represent the majority of integrin adhesive 
interactions (Shiokawa et al. 1999). Collagens and laminin have their own binding sites for 
integrins (Calderwood et al. 1997). In addition, some ECM molecules can also directly act as 
inflammatory stimuli by inducing transcription of proinflammatory genes (Fui et al. 2010). 
These ECM molecules display a class of endogenous signals or damage-associated molecular 
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patterns (DAMPs) molecules (Fui et al. 2010). Expression of these molecules is specifically 
induced upon tissue injury, for example the expression of tenascin-C, biglycan or fibronectin 
(Midwood et al. 2009; Fui et al. 2010). 
-Collagens  
Collagens (COLs) are the most abundant proteins found in the animal kingdom. It is the major 
protein comprising the ECM (Van der Rest & Garrone 1991; Gay & Miller 1979). There are 
at least 30 different collagen genes dispersed through the human genome (Van der Rest & 
Garrone 1991). These 30 genes generate proteins that combine in a variety of ways to create 
over 20 different types of collagen fibrils (Van der Rest & Garrone 1991; Gay & Miller 
1979). Types I, II and III COL are the most abundant types in formation of fibrils (Tomoaki et 
al. 2005; Van der Rest & Garrone 1991). Type IV COL forms a two-dimensional reticulum 
and is a major component of the basal lamina (Tomoaki et al. 2005; Van der Rest & Garrone 
1991). The fundamental higher order structure of COLs is a long and thin diameter rod-like 
protein (Schuppan et al. 2001). 
Collagen type I is the most abundant component of the ECM and is composed of glycine- and 
prolinerich two-a1(I) and one-a2(I) chains (Ramirez et al. 2006). The pro-COL1A1 and 
COL1A2 polypeptide chains are synthesized by fibroblasts, osteoblasts or odontoblasts 
(Ramirez et al. 2006). 
Type III collagen is a member of the fibrillar collagen family and is a homotrimer composed 
of a single α type chain (Tomoaki et al. 2005; Van der Rest & Garrone 1991).Type III COL is 
a component of the small argyrophilic collagen fibers that characterize reticular connective 
tissue (Gay & Miller 1979). It can be present in banded collagen fibrils regardless of fibril 
diameter (Van der Rest & Garrone 1991). Type III COL is co-expressed in most tissues with 
type I COL and can also form heterotypic fibrils with type I COL (Tomoaki et al. 2005). 
Studies with monoclonal antibodies suggested that type III COL is along with COL type I a 
component of straight fibrils (Van der Rest & Garrone 1991; Tomoaki et al. 2005).  
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-Fibronectin   
Fibronectin (FN) is a ubiquitous ECM glycoprotein that is assembled into a fibrillar matrix in 
all tissues (Purva et al. 2010). FN molecules typically exist as dimers composed of two 
subunits linked by a disulphide bond: Due to alternative splicing; at least 20 different variants 
of fibronectin are present in humans (Pankov and Yamada, 2002; Murray 2010). According to 
its solubility, FN can be subdivided in two broader categories; soluble plasma FN and less-
soluble cellular FN (Purva et al. 2010; Murray 2010; Pankov and Yamada, 2002). The basic 
domain structure of both plasma and cellular FN is homologous and contains RGD (Arg-Gly-
Asp) binding sites. These binding sites are responsible for interaction with integrin α5β1 and 
integrin αvβ3 and are therefore critical for fibronectin-cell interaction (Shiokawa et al. 1999; 
Murray 2010). FN contributes to the ECM by providing a degree of elasticity following the 
formation of fibrils (Purva et al. 2010; Murray 2010). FN fibrillogenesis occurs following 
binding to integrin α5β1 that elicits the formation of a dense network of fibrils on the cell 
surface (Murray 2010; Wierzbicka-Patynowski and Schwarzbauer 2003).  
-Tenascin-C  
Tenascins are proinflammatory ECM glycoproteins. Four isoforms have been recognized in 
vertebrates: tenascin-C, tenascin-X, tenascin-R and tenascin-W (Jones and Jones 2000; Peter 
& Frederick 2000).  
Tenascin-C (TNC) polypeptides form a hexabrachion and were discovered as first of the 
tenascin family (Peter & Frederick 2000). TNC is secreted by mesenchymal cells and is 
highly expressed in adult lung parenchyma following acute lung injury (Jones and Jones 
2000; Kaarteenaho-Wiik et al. 2001). High TNC levels are also associated with chronic 
inflammation in auto-immune diseases, such as rheumatoid arthritis and in tumor stroma 
(Midwood & Orend 2009; Midwood et al. 2009; Fui et al. 2010). Its expression can be 
modulated by many factors, including growth factors, mechanical stress, inflammatory 
cytokines and MMPs (Fui et al. 2010).  
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Several studies have shown that TNC mediates a number of cellular activities. For example, it 
stimulates the migration and proliferation of cells (Fui et al. 2010). It also interacts with 
fibronectin (FN), and supports adhesion of a variety of cell types including fibroblasts and 
endothelial cells (Chang et al. 1995; Maseruka et al. 1997; End et al. 1992; Fui et al. 2010). 
TNC induces cytokine synthesis in primary human macrophages and synovial fibroblasts via 
activation of toll-like receptors 4 (TLR4) pattern recognition receptor (Midwood et al. 2009). 
Also, it can stimulate cytokine and matrix metalloproteinase (MMPs) synthesis in murine 
synovial fibroblasts via activation of α9 integrins (Kanayama et al. 2009; Fui et al. 2010). 
Furthermore, TNC induces inflammatory mediators and promote matrix degradation in 
osteoarthritic cartilage (OA) (Lisha et al. 2011). 
 
1.1.1.3.2. Matrix metalloproteinases and their inhibitors 
Matrix metalloproteinases (MMPs) are enzymes that belong to the family of zinc-containing 
endopeptidases collectively assigned to the metzincin superfamily (Woessner 1994). The 
metzincin superfamily comprises enzymes with similar metalloproteinase domains; this 
superfamily is further subdivided into discovered multigene families: astacins, seralysins, 
adamalysins and MMPs (Overall & Lopez-Otin 2002; Woessner 1994).  
MMPs have many roles during development of wound healing or lung fibrosis. MMPs are 
expressed at very low levels in normal healthy tissues (Nagase et al. 1999). In contrast, MMP 
expression can be detected in all repair or remodeling processes, in all diseased or inflamed 
tissues and in all cell types grown in culture (Parks et al. 2004). The production of MMPs and 
other proteases is described in various cells such as granulocytes, macrophage, epidermal 
cells and fibroblasts/ myofibroblasts (Parks et al. 2004; Ruiz et al. 2003). MMPs play a major 
role on cell behaviors such as cell proliferation, migration (adhesion/dispersion), 
differentiation, and apoptosis (Parks et al. 2004; Overall & Lopez-Otin 2002). 
In early stages of fibrosis development, the MMPs regulate the efficiency of leucocytes 
infiltration and cytokine and chemokine secretion (Dean et al. 2008; Roderick et al. 2006; 
19 
PhD thesis Abdulaleem Alnajar 
Philippe and Claude 2007; Parks et al. 2004). In later stages, MMPs and their inhibitors 
(including the tissue inhibitors of MMPs (TIMPs)) regulate the collagen turnover and the 
ECM remodeling (Nagase et al. 1999; Ji Kim et al. 2009; Ruiz et al. 2003). Also, MMPs 
cleave many other types of peptides and proteins; but they have also many other important 
functions that may be independent of proteolytic activity (Parks et al. 2004; Nagase et al. 
1999).  
Human MMPs are classified into six different subgroups: collagenases, gelatinases, 
stromelysins, matrilysins, membrane type MMPs, and other MMPs (Woesser 1994; Ruiz et al. 
2003). Collagenases (MMP-1, MMP-8 and MMP-13) degrade mainly fibrillar collagens, 
whereas gelatinases (MMP-2 and MMP-9) have, among others, substrate affinity for 
basement membrane type IV collagen, thus the collagenases and gelatinases play an important 
role in fibrosis (Ruiz et al. 2003; Ji Kim et al. 2009). Matrilysin (MMP-7) was identified by 
transcriptional profiling analysis as significantly upregulated in bleomycin-induced lung 
fibrosis (Zuo et al. 2002).  
MMP-12 is mainly produced by macrophages and has been shown to be associated with 
inflammatory skin diseases, inflammatory respiratory disease, atherosclerosis and cancers 
(Soazig et al. 2005; Vincent et al. 2009). Furthermore, MMP-12 is an important inflammatory 
mediator in acute and chronic pulmonary inflammatory diseases, such as pulmonary fibrosis 
and chronic obstructive pulmonary disease (COPD) (Belvisi et al. 2003; Soazig et al. 2005). 
The major substrates for MMP-12 are the elastic ECM components such as elastin but MMP-
12 can also digest collagen type I, fibronectin and proteoglycans (Vincent et al. 2009). In 
addition to that, MMP-12 regulates the cytokines and chemokines function. For example, it 
specifically cleaves human ELR+CXC chemokines (CXCL1, -2, -3, -5, and -8) at Glu-Leu-
Arg (ELR) motif, which results in lose of chemotactic activity (Dean et al. 2008). 
Furthermore, MMP-12 processes and inactivates monocyte chemotactic proteins CCL2, -7, -
8, and -13 during acute inflammation (Dean et al. 2008) and is, thus, an important component 
in ceasing the acute inflammation phase during wound healing. 
Generally, MMPs are secreted into the extracellular space or anchored to the plasma 
membrane as inactive proenzymes (Bode et al. 1999; Nagase et al. 1999), thus, they require 
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activation. In vivo, MMPs are generally activated by other proteinases and in vitro, MMPs are 
activated by chemical and physical agents such as aminophenylmercuric acetate (APMA), 
low pH and heat treatment (Parks et al. 2004; Visse & Nagase 2003). The catalytic activity of 
MMPs is tightly regulated at multiple levels including gene expression (transcription and 
translation), compartmentalization and inhibition by their endogenous inhibitors and the tissue 
inhibitors of metalloproteinases (TIMPs) (Nkyimbeng Takwi 2008; Visse & Nagase 2003; 
Nagase et al. 1999).   
Tissue inhibitors of metalloproteinases (TIMPs) are specific regulators of MMP activity that 
bind and inhibit their specific active MMPs (Visse & Nagase 2003; Nkyimbeng Takwi 2008). 
In vertebrates the TIMP family consists of four members, TIMP-1, TIMP-2, TIMP-3, and 
TIMP-4 (Nkyimbeng Takwi 2008; Brew et al. 2000). Their expression is regulated during 
development and tissue remodeling. TIMPs have been shown to bind with high degree of 
specificity to the proenzyme forms of MMP-2 and MMP-9, an interaction that provides an 
extra level of MMP activity regulation (Nkyimbeng Takwi 2008; Olson et al. 1997). 
Moreover, TIMP-1 and TIMP-2 are capable to inhibit the activities of all known MMPs and 
playa key role in maintaining the balance between extracellular matrix deposition and 
degradation in different physiological processes (Brew et al. 2000; Nkyimbeng Takwi 2008; 
Visse & Nagase 2003). 
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1.1.6. Animal models for lung fibrosis 
To study the role of FHL2 in development of lung fibrosis, we chose the bleomycin-mediated 
lung fibrosis model, because bleomycin-induced fibrosis is easily reproducible in different 
species of mammals (e.g., mouse, rat, dog and pig) and is clinically relevant. It can be 
delivered intratracheally, intravenously, intraperitoneally or intranasally, which results in 
development of fibrosis within a time frame between 14-28 days (Walters et al. 2008; 
Bethany 2008; Moore & Hogaboam 2008). 
Bleomycin (BLM) is a glycopeptide antibiotic produced by the bacterium Streptomyces 
verticillus and was discovered in 1966, by Homao Umezawa (Umezawa et al. 1966). The 
commercially available form of BLM consists of predominantly BLM- A2 (55-70%) and 
BLM- B2 (25-32%) and the Figure 6 show the chemical structure of bleomycin (Hay et al. 
1991). BLM is a cytostatic drug commonly employed in the treatment of cancer and 
Hodgkin`s lymphoma (Benntt and Reich 1979). As a side effect of its therapeutic use, 
bleomycin induces in some patients a chronic pulmonary inflammation that may progress into 
fibrosis (Mouratis & Aidinis 2011; Hay et al. 1991). The BLM molecule has two main 
structural components; a bithiazole component which partially intercalates into the DNA 
helix, and pyrimidine and imidazole components which bind iron and oxygen forming an 
activated complex capable of releasing damaging oxidants in close proximity to the 
polynucleotide chains of DNA (Figure 6) (Hay et al. 1991). BLM is also able to cause cell 
damage independent from its effect on DNA by inducing lipid peroxidation (Breuer et al. 
1995; Bethany 2008; Hay et al. 1991). Also, BLM induces lung epithelial and endothelial 
cells apoptosis which is a key event in progression of lung fibrosis (Mungunsukh et al. 2010; 
Fridlender et al. 2007). The side effect of BLM is mostly basen on augmented concentration 
of reactive oxygen species, decrease in nicotinamide adenine dinucleotide (NAD) and 
adenosine triphosphate (ATP), and overproduction of mature collagen fibrils (Breuer et al. 
1995; Bethany 2008).  
By intratracheal injection, the BLM causes a lung injury, which becomes manifested in 
alveolar cells damage, interstitial edema and influx of inflammatory cells. This may lead to 
22 
PhD thesis Abdulaleem Alnajar 
development of lung fibrosis, characterized by activation of fibroblast and enhanced 
deposition of matrix proteins (Hay et al. 1991; Nuno et al. 1998; Marios & Vassilis 2011).  
The mouse lung fibrosis resembles the features of the human idiopathic lung fibrosis, but in 
contrast to the human lung fibrosis, the bleomycin-induced lung fibrosis in mice is transient 
(Degryse et al. 2011). 
 
 
Figure 6: The chemical structure of bleomycin and its active sites (bithiazole ring and pyrimidine and imidazole 
structures) (Hay et al. 1991). 
 
 
 
 
 
 
Bithiazole 
Pyrimidine 
Imidazole 
 
23 
PhD thesis Abdulaleem Alnajar 
1.2. The LIM-only protein “FHL2” 
1.2.1. LIM proteins 
FHL2 is an adaptor protein and belongs to the group of LIM proteins that regulates diverse 
processes in the cell. These include; the control of cell differentiation and growth. These 
proteins can either associate with the actin cytoskeleton or could be responsible for the 
transcription. LIM proteins make are able to interact with numerous cellular proteins, 
allowing formation of protein clusters with different complexity and specific activity (Bach 
2000; Henke 2007; Kadrmas and Beckerle 2004; Gabriel et al. 2009).  
The nomenclature of LIM derives from LIN-11 (C. elegance-linage protein), ISL-1 (rat 
insulin enhancer binding protein) and MEC-3 (C. elegance-linage transcription factor) 
(Nordhoff et al. 2012). A LIM domain is composed of two finger motifs, which bind two zinc 
ions and mediate interactions with other proteins (Figure 7A) (Bach 2000; Dawid et al. 1998; 
Kadrmas and Beckerle 2004; Meyer 2008). Depending on the presence of additional motifs, 
LIM proteins are grouped into four main families: nuclear-only, LIM-only, LIM-actin 
associated and LIM-catalytic proteins (Kadrmas and Beckerle 2004; Gabriel et al. 2009).  
FHL proteins belong to the subset of the LIM-only proteins because they contain only LIM 
domains. FHL proteins have a certain feature in their structural design: they contain aspecific 
number of LIM domains, namely, four-and-half LIM domains (FHL). Thus, they consist of 
four double and one single zinc finger and therefore, they can bind 9 zinc ions totally, see 
Figure 7B (Morgan and Madgwick 1996; Genini et al.1997). 
A)   
B)     
Figure 7: (A) Schematized structure of a LIM domain: the double zinc finger motif (B) Structure of FHL2 
(Four-and-half LIM domains). (Zn: zinc, C: cysteine, H: histidine, X: any amino acid) (Meyer 2008). 
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1.2.2. FHL subtypes  
There are several subtypes of FHL proteins, they include FHL1, FHL2, FHL3, FHL4 and 
ACT (Activator of CREM in testis), which are similar in their structural design (Morgan and 
Whawall 2000). The tissue-specific occurrence of FHL proteins and ACT is different. FHL1 
is the only protein of the FHL family with a relatively ubiquitous distribution in human 
tissues (Morgan and Magdwick 1999a). FHL2 is found to be particularly strong expressed in 
the heart and skeletal muscles and to a less extent in the ovary, testis, prostate and other 
endocrine structures (pituitary gland, adrenal medulla) (Chan et al. 1998; Fimia et al. 2000; 
Genini et al. 1997; Muller et al. 2000; Henke 2007; Scholl et al. 2000; Johannessen et al. 
2006). FHL3 is strongly expressed in heart and skeletal muscles, but only weak in the ovary, 
spleen and adrenal gland (Morgan and Madgwick 1999a; Henke 2007). FHL4 and ACT are 
synthesized specifically in testis (Morgan and Madgwick 1999b).  
 
1.2.3. Genetic coding and structure of FHL2 
The human FHL2 gene was discovered in 1997 on the chromosomal region 2q12-q13 and 
consists of 7 exons (Figure 8) (Chan et al. 1998). By comparing this gene sequence with the 
nucleotide database of the Gene Bank, it was found that FHL2 is identical with two other 
known proteins. One of them, it is SLIM-3 (skeletal muscle LIM-protein 3), which showed a 
particularly strong expression in the skeletal muscles (Morgan and Madgwick 1996). The 
other molecule with a homologous structure to FHL2 was DRAL (down regulated in 
rhabdomyosarkoma LIM protein) (Genini et al. 1997). Actually, SLIM-3, DRAL and FHL2 is 
the same protein. Different researches described it and gave the proteins different names 
(Johannessen et al. 2006; Genini et al. 1997; Henke 2007;  Morgan and Madgwick 1996). 
The FHL2 gene is transcribed into a 1.5 kb RNA molecule, which is translated into a protein 
with 279 amino acids (Johannessen et al. 2006). The comparison of the amino acid sequence 
between FHL2 and the other proteins of the FHL family, including ACT, shows that it is not 
only similar in the structural design, but also in the sequence of their gene, which suggests a 
common genetic ancestry (Johannessen et al. 2006). Thus, human FHL2 protein is 47.9% 
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identical with human FHL1, 51.8% with human FHL3, 47.1% with mouse FHL3 and 58.5% 
with ACT (Morgan and Whawell 2000; Johannessen et al. 2006).  
 
 
Figure 8: Schematic representation of the fhl2. Exons are depicted with boxes bound to each other by 
interrupted lines representing the introns. Numbers in the boxes indicate the size of the exons in bp. The smaller 
boxes in front of exon 1 and intron 2 illustrate the presence of putative transcription factor binding sites 
(Johannessen et al. 2006).   
 
1.2.4. Expression and cellular localization of FHL2 
As already mentioned, FHL2 shows the highest expression in heart cells, but can also be find 
in in different other cell types, including myoblasts, prostate epithelial cells, 
rhabdomyosarcoma cells, fibroblasts and several types of tumor cells (Gabriel et al. 2009; 
Gabriel et al. 2004; Wixler et al. 2000). The LIM-only protein FHL2 is involved in a wide 
range of cellular processes, which is reflected by its different localization in the cell. First, it 
was found to be localized at the cell membrane where it participates in cell adhesion, cell 
identity and cell differentiation (Muller et al. 2000; Wixler et al. 2000). Second, FHL2 
regulates signal transduction by interaction with various cytoplasmatic and cytoskeletal 
proteins (Muller et al. 2000; Wixler et al. 2007; Park et al, 2008). Third, FHL2 was found in 
the nucleus, where it works as a transcriptional cofactor selectively stimulating expression of 
specific DNA segments (Du et al. 2002; Labalette et al. 2004; Li et al. 2001; Muller et al. 
2002). 
The molecular mass of the FHL2 protein is 32 kDa which is well below the cut-off (50-kDa) 
for the active transport through the nuclear pores, which may explain the lack of an apparent 
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nuclear localization signal and/or nuclear export signal but could lead to passive shuttling 
between the cytoplasm and the nucleus (Wixler et al. 2000; Wixler et al. 1999; Samsonet al. 
2004). 
The localization and expression of FHL2 is controlled by various stimuli. For example; pro-
fibrotic cytokines (such as TGFβ) and S1P (sphingosine-1-phosphate) induce its expression, 
while pro-inflammatory cytokines TNFα and IL-1 downregulate it (Joos et al. 2008; Phillipar 
et al. 2004; Meyer 2008). 
 
1.2.5. Function of FHL2 and its interaction partners 
FHL2 is able to interact with many different proteins and depending on the interaction 
partner, different LIM-domains are involved. FHL2 can interact with more than 50 different 
proteins (Johannessen et al. 2006). 
FHL2 was found to play a role in the regulation of signal transduction, gene expression and 
cytoskeleton modulation, as well as in cell adhesion, survival and mobility (Bai et al. 2005; 
Muller et al. 2002; Johannessen et al. 2006).  
FHL2 interacts with the cytoplasmic part of different α-integrin chains like, α3A, α3B, α7A 
and α7B subunits (Samson et al. 2004; Wixler et al. 2000; Wixler et al. 1999), but also with 
several β subunits (Samson et al. 2004; Wixler et al.2000). Further, FHL2 interacts with 
various structural proteins of the cytoskeleton, such as actin, myosin, titin, and vinculin, 
suggesting a role of FHL2 in the organization of the cytoskeleton (Coghill et al. 2003; El 
Mourabit et al. 2004; McGrath et al. 2006; Johannesson et al. 2006). 
Further studies showed that FHL2 is involved as an adapter protein in the assembly of focal 
contacts and that it fulfills this function through interaction with different integrins and FAK 
(Park et al. 2008). Furthermore, FHL2 controls cell migration and besides this the 
development of focal contacts and the assembly of extracellular matrix proteins (Wixler at al, 
2007; Park et al, 2008). The interaction between FHL2 and ERK lead to prevention of 
passage of ERK into the nucleus, which in turn affects ERK-dependent gene expression 
(Purcell et al. 2004).  
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The function of FHL2 as a cofactor of transcription may vary according to interaction partners 
and cell type, because FHL2 can act both as activator and repressor (Johannessen et al. 2006). 
As activator, FHL2 selectively interacts with the androgen receptor (AR) and acts as a 
coactivator for the expression of AR-specific genes (Muller et al. 2000). FHL2 also acts as a 
coactivator of the CREB-mediated gene expression (Fimia et al. 2000; Johannessen et al. 
2007). Further, FHL2 directly binds to β-catenin and acts as a regulator of β-catenin-Lef/Tcf-
transcription complexes (Martin et al, 2002; Labalette et al. 2004; Wei et al. 2003). In this 
respect, FHL2, however, shows a dual function, which is cell type-dependent. It inhibits the 
Lef /Tcf-driven transcription in myoblasts, but increased it in epithelial cells (Martin et al. 
2002; Chen et al. 2003).  
FHL2 has been shown to interact with the proteins of the AP-1 complex, which is a 
heterodimer of protonkogenes c-Jun and Fos and one of the key transcription factors in MMP 
expression (Morlon and Sassone-Corsi 2003; Martin et al. 2007). Furthermore, the FHL2 
deficiency results in increased translocation of p65 to the nucleus, as well as in increased 
transcription of NF-kB-dependent genes, assuming that it regulates the activity of the NF-kB 
pathway (Bai et al. 2005).  
 
1.2.6. FHL2 is an important mediator in inflammation, wound healing and fibrosis 
Inflammation is always a consequence of tissue injuryand results either in wound healing or 
fibrotic disease (Wynn 2011; Pottier et al. 2007). The latter is characterized by migration of 
immune-inflammatory cells, activation of fibroblasts and dysregulated synthesis of 
extracellular matrix proteins (Wynn 2011; Razzaque & Taguchi 2003). FHL2 is highly 
expressed in activated fibroblasts and shuttles between the cell membrane and nucleus playing 
an important role during development of the disease (Muller et al. 2002; Johannessen et al. 
2006).  
In inflammation, FHL2 is an important regulator of the innate cellular immune response to 
influenza A virus (IAV) infection (Nordhoff et al. 2012). Also, FHL2 promotes epithelial-
mesenchymal transition in colon cancer (Wenjing et al. 2010). Konig and others showed that 
FHL2 is an important regulator of dendritic cell (DCs) migration towards the chemotactic 
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factor CCL19 (Konig et al. 2010). The LIM-only protein FHL2 regulates interleukin-6 
expression through p38MAPK mediated NF-kB pathway in muscle cells, the pleiotropic 
cytokine that play an important role in inflammatory response (Chi-Hang et al. 2012). 
Through association with proteins of the TRAF (tumour necrosis factor receptor-associated 
factor) family FHL2 sequesters TRAF6 from RANK receptor in osteoclasts, inhibiting 
activation of the NF-kB pathway and stimulating bone resorption (Bai et al. 2005). Also, 
FHL2 has a role in the limitation of cytokine- induced MMP expression and constitutes an 
important regulator of inflammatory tissue damage in arthritis (Meyer 2008). 
Fhl2- deficient mice revealed a delayed skin wound healing, reduced migration of 
mesenchymal precursor cells, reduced expression of α- smooth muscle actin (α-SMA), and 
impaired wound contraction (Wixler et al. 2007). Fhl2 is strongly up-regulated in α-SMA 
positive mesenchymal cells of wounded skin and acts there as a coactivator of serum response 
factor-mediated α-SMA expression. In addition to the support of the aSMA-mediated 
myofibroblast contraction, Fhl2 also influences the migration capability of fibroblasts, which 
has to entry the wound area for replacing the clot and forming the granulation tissue (Wixler 
et al. 2007).  
During cell adhesion and ECM assembly, FHL2 interacts with several α- and β- integrins, as 
well as with FAK and α-actinin regulating formation of  focal adhesions sites and the 
capability of cells to generate mechanical forces (Wixler et al. 2000). Inactivation of FHL2 
shows impaired focal adhesion clustering, a less-organized cytoskeleton, reduced Rac1 
activation, lowered cell motility, and impaired ECM assembly (Park et al. 2008; Wixler et al. 
2000). Deficiency of FHL2 also results in enhanced FAK phosphorylation (Y86 & Tyr925), 
enhanced integrin-dependent activation of Ras-Raf-MEK-ERK pathway, less bundled stress 
fibers and reduced contraction of collagen matrices (Wixler et al. 2007; Park et al. 2008).  
In additional to its role in regulation of the MAP kinase ERK signaling pathway, FHL2 is also 
involved in regulation of NF-kB pathway and p38 MAP kinase signaling cascades, which in 
turn play a role in development of fibrotic disease (Bai et al. 2005; Muller et al. 2002). 
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Further, FHL2 upregulates as a cofactor of transcription the expression of aSMA and some 
matrix proteins, but inhibits the expression of matrixmetalloproteinases-1, -3 and -13 (MMP) 
(Kirfel et al. 2008; Philippar et al. 2004; Meyer, 2008). FHL2 may act as a cofactor of Jun and 
Fos that are known as transcription factors of several cytokines (such as TNF-α and IL-2) and 
collagenases MMP-1(Morlon and Sassone-Corsi 2003). 
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Aims of the thesis: 
Lung fibrosis is a progressive fibrosing disease of unknown aetiology. It causes scarring of 
alveolar compartments of the lung where gas exchange occurs and results in tissue damage. It 
is characterized by activation of tissue fibroblasts and deregulated synthesis of extracellular 
matrix proteins. Available data increasingly indicate that chronic inflammation and aberrant 
wound healing play an important role in the development of the disease. 
FHL2 (four-and-a-half LIM domain protein 2) is a scaffolding protein that is able to interact 
with numerous membranes, cytosolic and nuclear proteins. By formation of a protein complex 
with integrins and focal adhesion kinase, FHL2 supports clustering of integrins and integrin-
driven assembly of matrix proteins. By interaction with cytosolic proteins FHL2 is involved 
in regulation of NF-kB and MAPK signalling cascades. Besides modulating signalling 
molecules, FHL2 shuttles between cytosol and nucleus, regulating as a cofactor of 
transcription the expression of aSMA and some matrix proteins, but inhibiting the expression 
of matrix metalloproteinases. During skin wound healing FHL2 is upregulated in activated 
fibroblasts, but only transiently. Pro-fibrotic cytokines, such as TGFβ and S1-P (sphingosine 
1-phosphate) induce its expression, while the pro-inflammatory cytokine IL-1 downregulates 
the gene.  
In this study we aimed to define the role of the FHL2 protein in fibrotic alterations. We chose 
the BLM-induced lung fibrosis, which is the best studied animal model for pulmonary fibrosis 
yet and compared the development of lung fibrosis between FHL2-WT and FHL2-KO mice. 
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2. Materials and methods 
2.1. Materials 
2.1.1. Chemicals materials 
Table 1: 
Material Company 
Acrylamide / bisacrylamide 30% Carl Roth, Karlsruhe, Germany 
Adenosine triphosphate (ATP) Carl Roth, Karlsruhe, Germany 
Agar Oxoid, Hampshire, United Kingdom 
Ammonium peroxodisulfate (APS)   Carl Roth, Karlsruhe, Germany 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
Chloroform  Sigma; Germany 
Dithiothreitol (DTT) Carl Roth, Karlsruhe, Germany 
Ethanol  Carl Roth, Karlsruhe, Germany 
Ethylenediaminetetra acetic acid (EDTA) Carl Roth GmbH & Co., Germany 
Glycerol   Carl Roth, Karlsruhe, Germany 
Glycin  Carl Roth, Karlsruhe, Germany 
H2O2 Merck, Darmstadt, Germany 
KH2PO4 Carl Roth GmbH & Co., Germany 
Leupeptin Sigma-Aldrich, Munich, Germany 
Luciferin                                                        Applichem, Darmstadt, Germany 
Luminol Carl Roth, Karlsruhe, Germany 
Magnesium acetate Carl Roth, Karlsruhe, Germany 
Methanol  Carl Roth, Karlsruhe, Germany 
MgCl2 Carl Roth, Karlsruhe, Germany 
Non-fat dried milk powder blotting grade Applichem, Darmstadt, Germany 
NP-40    (IgePal) Carl Roth, Karlsruhe, Germany 
P-coumaric acid Sigma-Aldrich, Munich, Germany 
Pepton                                                            Carl Roth GmbH & Co., Germany 
Ponceau S red Carl Roth GmbH & Co., Germany 
2-Propanol  Carl Roth, Karlsruhe, Germany 
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Sodium Chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium deoxycholate Carl Roth, Karlsruhe, Germany 
Sodium dodecylsulfat (SDS) Carl Roth, Karlsruhe, Germany 
Sodium glycerophosphate Sigma-Aldrich, Munich, Germany  
Sodium pyrophosphate Sigma-Aldrich, Munich, Germany 
Sodium vanadate Carl Roth GmbH & Co., Germany 
Sodium-MES Carl Roth, Karlsruhe, Germany 
TEMED  Carl Roth, Karlsruhe, Germany 
TRIS-HCl  Carl Roth GmbH & Co., Germany 
Triton-X-100  Sigma-Aldrich, St.Loius, MO, USA 
Trizol reagent Life technologies, USA 
β-mercaptoethanol  Carl Roth, Karlsruhe, Germany 
 
2.1.2. Buffer and solutions 
Triton lysis buffer: 
Tris-HCl pH 7.4 20 mM NaCl 137 mM 
MgCl2 10 mM Triton X-100 1% 
Glycerol 10% EDTA pH8 2 mM 
Sodium glycerophosphate           50 mM            Sodium pyrophosphate 20 mM 
Aprotinin                                     5mg/ml           Leupeptin 5 mg/ml 
Pefablock                                    200 mM          Sodium ortho-vanadate) 2 mM 
RIPA lysis buffer: 
Tris-HCl pH8 25 mM NaCl 137 mM 
Glycerol 10% Sodium dodecylsulfat (SDS) 0.1% Sodium 
deoxycholate 0.5% NP-40 (IgePal) 1% EDTA  
Aprotinin                                    5mg/ml Leupeptin 5 mg/ml 
Pefablock                                    200 mM Sodium ortho-vanadate) 2 mM 
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SDS-PAGE sample buffer (4x Laemmli) 
1M  Tris / HCl pH 6.8 10 ml β-mercaptoethanol 5 ml 
87% Glycerol 23 ml              Sodium dodecoelsulfat (SDS) 5 g 
2% bromophenol blue 2.5 ml             1M EDTA 0.2 ml 
d. H2O ad 50 ml 
SDS-PAGE separating gel: 
Tris-HCL pH 8.9                        370mM           Sodium dodecylsulfat (SDS)      0.1%          
APS                                             0.1%               TEMED                                      0.02%     
Acrylamid/bisacrylamid             7.5-15% 
SDS-PAGE stacking gel: 
Tris-HCL pH 6.8                        178mM           Sodium dodecylsulfat (SDS)      0.1%         
APS                                             0.1%               TEMED                                      1%     
Acrylamid/bisacrylamid             4.3% 
SDS-PAGE running buffer: 
Tris-HCL pH8.4                         25 mM            Glycine                                       250 mM 
Sodium dodecoelsulfat (SDS)    0.1% 
Ponceau S reagent 
Ponceau S                                   2%                   Trichloroacetic TCA                  3% 
Transfer buffer for western blots (blotting buffer): 
Tris-HCL pH8.4                         25 mM            Glycine                                       192 mM 
Methanol                                    10% 
ECL detection reagent 
1M Tris / HCl  pH 8.5                2µl                   250 mM Luminol                       200 µl                                     
90 mM p-coumaric acid             80µl                 H2O                                            ad 20 ml                                 
35% H2O2                                  6.1 µl ad freshly   
Stripping puffer for western blotting membranes: 
Tris / HCl pH 6.8                        62.5 mM         β-mercaptoethanol                     100 mM 
Sodium dodecoelsulfat (SDS)     2% 
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TBS- Triton X-100 buffer (20x): 
Tris-HCl pH 7.6                          50 mM            NaCl                                          155 mM 
Triton X-100                               0.2% 
Luciferase harvesting buffer: 
Sodium-MES pH7.8                   50 mM            Tris-HCL pH7.8                         50 mM      
DTT                                            1 mM              Triton X-100                               0.2% 
Luciferase assay buffer: 
Sodium-MES pH7.8                   125 mM          Tris-HCL pH7.8                         125 mM     
Magnesium acetate                     25 mM            ATP                                             49 mM 
Luciferin solution: 
Luciferin                                     0.95 mM         KH2PO4 pH7.8                          5 mM 
Freezing medium of eukaryotic cells 
D-MEM high glucose                 80%                FCS                                             10% 
DMSO                                        10% 
LB-medium: 
Pepton                                         1% (w/v)         yeast extract                               0.5% (w/v)     
NaCL                                          1% (w/v) 
LB-Amp-medium: 
LB-Medium                                                        Ampicillin                                  100 µg/ml 
LB-Agar-platten: 
LB-Medium                                                        Agar                                           1.5 % (w/v) 
Paraformaldehyde (PFA 4%): 
For preparation of a 20% stock solution of paraformaldehyde (PFA), 20g of PFA was added 
to 80 ml of PBS. Then, 2µl of 5N NaOH per 1ml of PBS was added and heating at 65 °C for 
approx 15-20 min until the granules fully dissolved and the solution became translucent. 
Finally, the solution was filtered and stored at -20 °C. For 4% PFA, the stock solution was 
dilutied by PBS. 
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2.1.3. Animal injection and histological materials 
Table 2: 
Material / Substance Company 
AZAN trichrome Roth, Karlsruhe, Germany 
Cover slips 24x36mm  VWR, Menzel, Germany 
Diethyl ether (99.5%) Roth, Karlsruhe, Germany 
Eosin Y alcoholic solution Roth, Karlsruhe, Germany 
Formaldehyde alcohol free ≥37%  Roth, Karlsruhe, Germany 
Histological glass slides Superfrost Plus® Thermo scientific, Germany 
Hydrogen peroxide 30% pro analysi  Merck Darmstadt, Germany 
Isopropanol (99.8%)  Roth, Karlsruhe, Germany 
Mayer’s Hematoxylin solution  Roth, Karlsruhe, Germany 
Needles 20G (0.9mm x 25mm)  BD Biosciences, USA 
Paraffin  Allegiance Health Care, Corp. IL, U.S.A 
Paraffin embedding medium Paraplast Plus® Microm international GmbH, Germany 
Roti-Histol (Xylolersatz)  Roth, Karlsruhe, Germany 
Surgical materials (e.g. scissors, scalpel and 
tongs) 
FEATHER, Japan 
Syringes 1ml, 5ml, 10ml Inject Luer® BD Biosciences, USA 
Tissue-Tek Glas mounting medium SAKURA; Germany 
Universal-embedding cassettes y GML alfaplast, Germany 
 
Table 3: Injection solutions 
Solution/ Substance Company 
Bleomycin sulphate ® Sigma-Aldrich, St.Loius, MO, USA 
Clodronate liposomes Sigma-Aldrich, USA 
Control liposomes (PBS) Sigma-Aldrich, USA 
Ketamin 10% CEVA- Sante animale, Germany 
Phosphate buffered saline (PBS) Baxter S.A., München, Germany 
Starch4% REWE Market, Germany 
Xylazin 2% CEVA- Sante animale, Germany 
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2.1.4. Biological materials 
2.1.4.1. Cell culture materials 
- Eukaryotic cells:  
- HeLa cells: human epithelial cell line derived from a cervical cancer 
- HEK209 cells: human embryonic kidney cell line 
- Primary fibroblasts from wild-type mice 
- Primary macrophages from FHL2-deficient and wild-type mice 
 
- Bacterial strains:  
- Escherichia coli DH5a: for cloning / propagation of plasmid DNA (Grant et al., 1990). 
Genotype: F-endA1 hsdR17 (rm-, mk +) supE44 thi-1 α-recA1 gyrA96 relA1 Deor D 
(lacZYA-argF) U169 α80dlacZαM15 
 
- Plasmid vectors and promoters 
- pCS2+MT: eukaryotic expression vector for the expression of myc-tagged proteins 5x/6x 
(Wixler et al., 2000) 
- pCS2+MT/ FHL2: eukaryotic expression vector for expression of myc-tagged FHL2 
(Wixler; IMV, Muenster, Germany) 
-The human TNC promoter comprised a 2000 bp long sequence including the TATA box and 
the first 83 bp of the first exon. 
 
- siRNAs  
- siFHL2: sequence (5`  3` CAACGACUGCUUUAACUGU); Eurofins MWG Operon, 
Germany. 
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Table 4: Cell culture media, reagents and supplements 
Media / Supplements Company 
Ampicillin- antibiotic Sigma-Aldrich, Germany 
Bovine serum albumin (BSA) 35% MP Biomedicals, Heidelberg, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Munich, Germany 
D-MEM high glucose PAA laboratories, Austria 
Fetal Calf  Serum (FCS) Biochrom GmbH, Berlin, Germany 
Gentamicin- antibiotic PAA laboratories, Austria 
HiPerFect Transfection Qiagen: Roche, Mannheim 
Lipopolysaccharide(LPS) Sigma-Aldrich, Germany 
Opti-MEM Gibco Invitrogen, Darmstadt, Germany 
Penicillin/ streptomycin100x PAA laboratories, Austria 
Polyethylenimine (PEI) Sigma-Aldrich, Germany 
RPMI 1640 PAA laboratories, Austria 
Sodium hydrogen carbonate Gibco Invitrogen, Darmstadt, Germany 
Transformal growth factor-beta (TGF-β) R & D Systems GmbH, Wiesbaden-Engelstedt 
Trypan blue solution Sigma-Aldrich, Germany 
Trypsin-EDTA10x PAA laboratories, Austria 
Tumor necrosis factor-alpha (TNFα) Sigma-Aldrich, Germany 
 
2.1.4.2. Primers for RT-PCR 
The primers used were assigned using the Universal Probe Library Assay Design Center at 
www.roche-applied-science.com/sis. 
Table 5: 
cDNA Primer: 5`  3` 
(F= Forward primer, R= Reverse primer) 
probe Nr. 
Mouse-GAPDH F: gtccaccagcctgttgctgta 
R: cccactcttccaccttcgatg 
80 
Human-GAPDH F: gcatcctgggctacactgag 
R: tgctgtagccaaattcgttg 
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cDNA Primer: 5`  3` 
(F= Forward primer, R= Reverse primer) 
probe Nr. 
Mouse-FHL2 F: tgcgtgcagtgcaaaaag 
R: tgtgcacacaaagcattcct 
32 
Human-FHL2 F: gtgcaccaaccccatcag 
R: caccagtgagagggagcact 
59 
Mouse-TNC F: gggctatagaacaccgatgc 
R: catttaagtttccaatttcaggttc 
76 
Mouse-MMP12 F: ttgtggataaacactactggaggt 
R: aaatcagcttggggtaagca 
51 
Mouse-CD209a F: accaagaactgacccagttga 
R: cttggaagtgcgtccagtc 
51 
Mouse-IL-6 F: tgagatctactcggcaaacctgtg 
R: cttcgtagagaacaacataagtcagatacc 
SYBR Green 
Mouse-TNFα F: tcttctcattcctgcttgtgg 
R: ggtctgggccatagaactga 
49 
Mouse-TGFβ F: tggagcaacatgtggaactc 
R: cagcagccggttaccaag 
72 
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2.1.4.3. Antibodies and enzymes 
-Enzymes: 
Dnase I: Roche, Mannheim, Germany 
Colagenase A: Roche, Mannheim, Germany 
Rnase A: Invitrogen AG, Darmstadt, Germany 
Proteinase K: Roche, Mannheim, Germany 
 
-Antibodies: 
Table 6: Primary antibodies for Western blotting and IHC 
material targetprotein 
size 
using company 
Mouse-anti-ß-actin  42kDa  w. blot Sigma-Aldrich, Munich, Germany 
Monoclonal- anti-α-
Tubulin 
50 kDa w. blot Sigma-Aldrich, Munich, Germany 
Mouse- Anti-FHL2  
(clone F4B2-B11) 
32kDa w. blot Wixler et al., 2007 
Rabbit-anti-lamininγ1 180 kDa w.blot Wixler et al., 2007 
Rat- anti-TNC 190-240 kDa w.blot Abcam, UK 
Rabbit- anti-TNC  190-240 kDa ICH Epitomics, USA 
Rabbit- anti-FN  94-220 kDa w.blot Sigma-Aldrich, Munich, Germany 
Rabbit- anti-COL1  140-210 kDa w.blot Merck Chemicals GmBH, Germany 
Rabbit- anti-COL3 300 kDa w.blot Abcam, UK 
Mouse- anti-aSMA 42 kDa w.blot Sigma-Aldrich, Munich, Germany 
Rabbit- anti-MMP12  45 kDa ICH Biorbyt-Tools for 39cience,  Germany 
Rat- anti-F4/80  160 kDa ICH AbD sero Tec, Germany 
Rabbit- anti-CD3 23 kDa ICH Abcam, UK 
Goat- Pax-5 (C-20)  46 kDa ICH Santa Cruz Biotechnology, Germany 
Rabbit- anti-S100A9 13 kDa ICH Abcam, UK 
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Table 7: Primary antibodies for flow cytometry 
material company 
APC hamster-anti-mouse CD11c eBiosciences, Germany 
APC rat-anti-mouse CD8a eBiosciences, Germany 
APC-streptavidin BD Biosciences, Germany 
Biotin IL-6 anti-mouse eBiosciences, Germany 
Biotin TNFα anti-mouse eBiosciences, Germany 
biotin-labeled rat-anti-mouse GR-1  BD Biosciences, Germany 
FITC-rat-anti-mouse CD11b BD Biosciences, Germany 
FITC-rat-anti-mouse CD45.2 BD Biosciences, Germany 
PE CD4 rat-anti-mouse BD Biosciences, Germany 
PE MHCII rat-anti-mouse eBiosciences, Germany 
PE rat-anti-mouse F4/80 eBiosciences, Germany 
 
Table 8: Secondary antibodies 
material description using company 
anti-mouse IgG-HRP-lab. w. blot Amersham, Freiburg, Germany 
anti-rabbit IgG-HRP-lab. w. blot Amersham, Freiburg, Germany 
anti-goat IgG-HRP-lab. w. blot Santa Cruz, Heidelberg, Germany 
anti-rat IgG-HRP-lab. w. blot SIGMA, USA 
anti-mouse IgG biotin-lab. IHC Linaris GmbH Wertheim, Germany 
anti-rabbit IgG biotin-lab. IHC Linaris GmbH Wertheim, Germany 
anti-goat IgG biotin-lab. IHC Linaris GmbH Wertheim, Germany 
anti-horse IgG biotin-lab. IHC Linaris GmbH Wertheim, Germany 
Prestained protein marker  Sigma Aldrich, Karlsruhe 
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2.1.4.4. Molecular-biological kits 
- AMAXA- mause Machrophage Nucleofactor Kit:  AMAXA GmbH, Germany 
-BCA Protein Assay kit: Pierce, Bonn, Germany  
- Bradford Protein Assay Reagent: Bio-Rad, Muenchen, Germany  
- Brilliant II SYBR Green® QPCR Master Mix: Agilent, Waldbronn, Germany 
-High-Capacity cDNA Reverse Transcription Kit (ABI 4368814): AB Applied Biosystems 
- QIA filter Plasmid-Max-Kit: Qiagen, Hilden  
-Qiagen RNeasy® Mini kit: Qiagen, Hilden  
- Sircol collagen assay kit: Biocolor Ltd., U K 
- TagMan®-PCR Meister Mix: Roche, Mannheim, Germany 
- Vector® Red Alkaline Phosphatase Substrate Kit I, Vector Laboratories, via Linaris GmbH, 
Wertheim-Bettingen 
- Vector® Vectastain ABC Kit, Vector Laboratories, via Linaris GmbH, Wertheim-Bettingen 
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2.1.5. Consumables 
Table 9: 
Material Company 
Cell Culture Dishes Greiner Labortechnik, Solingen, Germany 
Cell Culture flasks Greiner Labortechnik, Solingen, Germany 
Cell strainer (Filter Falcon)- 70µm BD Biosciences, USA 
Disposable pipettes 5ml, 10ml, 20ml  Becton Dickinson Biosciences, Germany 
Eppendorf tubes 0.5ml, 1ml, 1.5ml , 2ml  Eppendorf, Germany 
Falcon tubes 15ml, 50ml  Becton Dickinson Biosciences, Germany 
Glass plates Bio-Rad, Muenchen, Germany 
Lysing matrix D tube MP Biomedicals, USA 
Nitrocellulose membrane protran Schleicher & Schuell, Dassel 
Whatman GB002 paper Schleicher & Schuell, Dassel 
 
2.1.6. Machines, systems and software 
Table 10: 
Machines, systems and software Company 
Acrylamide gel electrophoresis apparatus Bio-Rad, Muenchen, Germany 
Bacteria incubator Heraeus, Hanau, Germany 
shaking bacteria Infors, Bottmingen, Switzerland 
Bio Photometer Eppendorf, Hamburg, Germany 
Centrifuge (bench-top) 5810R Eppendorf, Hamburg, Germany 
Centrifuge Eppendorf 5417R Eppendorf, Hamburg, Germany 
CO2 Incubator for cell culture (Hera cell 240) Heraeus, Hanau 
Digital camera microscope  Zeiss, Goettingen, Germany 
Flow cytometry(FACSCalibur) Becton Dickinson, Heidelberg, Germany 
ELISA Reader Biotek, USA 
AxioVert 25 microscope Zeiss, Germany 
Liquid nitrogen tank (-181°C) Tec-Lab, Germany 
Luminometer LB96V EG&G Berthold, Bad Wildbach 
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Microtome HM 355S ThermoFisher scientific, Germany 
NanoDrop spectrophotometer Thermo Scientific, Germany 
Neubauer hemocytometer Merck KGaA, Darmstadt, Germany 
pH-meter Knick, Germany 
Roche- RT-PCR Cycler- 480II Roche, Mannheim, Germany 
Sterile hood (cells) BDK, Germany 
Tank western blot chamber Bio-Rad, Muenchen, Germany 
Digital detection system Stella  raytest Isotopenmeßgerate GmbH, Germany 
Thermcycler (N99nBiometra T Gradient) Eppendorf, Germany 
Tissue embedding machine EG 1150H  Leica Microsystems, Nussloch, Germany 
Ultra-Turrax Homogeniser type T8 IKA-Werke, staufen, Germany 
Water bath GFL type 1012, Burgwedel, Germany 
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2.2. Methods 
2.2.1. Animal methods 
Animal experiments were conducted with the approval of the ethics commission and in 
compliance with the guideline uses of experimental animals at the University Hospital of 
Muenster.  
In our experiment the following mouse strains were used: 
FHL2-/- mice (genetic background C57BL / 6), here referred also as FHL2 KO mice 
FHL2 +/+ mice (genetic background C57BL / 6), here referred also as WT mice 
These mice were used at age of 2-4 months to study the development of lung fibrosis after 
bleomycin treatment and the inflammatory status of this disease as well. 
 
2.2.1.1. Bleomycin administration 
Here, several WT and FHL2KO mice were used in the study. Pulmonary fibrosis was induced 
in mice by intranasal administration of a single dose of bleomycin (usualy 2U/kg body 
weight, in some experiments 3U/kg or 5U/kg we also used) that was reconstituted in PBS. 
Control animals received only PBS intranasally. After anesthesia of mice with 10 ml/g 
anesthesia solution (0.5 mlXylazin 2% and 0.5 ml Ketamin 10% in 9 ml PBS), the bleomycin 
solution was injected into the lungs, drop by drop via nose at a volume of 25-35μl/nose (total= 
50-70µl/mouse). The mice are weighted regularly (each 3 day) to define the changes of the 
body weight during the fibrosis development. 
For the analysis, mice were euthanized 7, 10, 14, 21 and 28 days after bleomycin or saline 
administration and the bronchoalveolar lavage fluid (BALF), the lung cells, lung tissue lysate 
or the intact lung tissue were isolated and analyzed by different methods.  
 
2.2.1.2. Depletion of macrophages in vivo 
For in vivo depletion of macrophages, clodronate liposomes were used. The clodronate 
(dichloromethylene bisphosphonate) is a non toxic drug as well as liposomes (Rooijen and 
Sanders 1994). The liposomes are used as a trojan horse for the intracellular introduction and 
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accumulation of clodronate, which acts as an effector molecule that induce apoptosis of 
macrophages and hence their depletion from organs and tissues (Rooijen and Sanders 1994). 
The mice were intravenously injected with 100µl/mouse of clodronate liposomes or PBS- 
liposomes as control and on the next day they were repeatedly injected with 75µl/mouse of 
the same solution but intranasally. On the following day, the mice were treated intranasally 
with 3U/kg BLM and 5 days later, the mice were received again clodronate or PBS- 
liposomes intranasally, 75µl/mouse.  
For analysis, mice were euthanized and the bronchoalveolar lavage fluid (BALF), blood 
samples, lung cells, lung tissue lysate and intact lung tissue were isolated and analysed by 
different methods.  
 
2.2.1.3. Preparation of bronchoalveolar lavage fluid and lung cells  
Euthanized mice were carefully lavaged by injecting 1ml of PBS supplemented with 2 mM of 
EDTA into a trachea using a syringe with 20 G cannula. The procedure was repeated twice, so 
that ~ 2ml of bronchoalveolar lavage fluid (BALF) were recovered from each mouse. The 
BALF was then centrifuged at 300xg for 10 minutes at 4°C, and the supernatant was aliquoted 
and frozen at -80°C until analysis.  
To obtain a single lung cell suspension, the lung tissue was cut into tiny pieces and placed in 
15ml falcon with 3-4 ml RPMI 1640 medium containing 0.7mg/ml colagenase A and 100 
Kunitz-Units/ml DNase I and incubated at 37°C in a water bath for 30 min, after which the 
digested tissue was pipetted several times through a 20 G syringe needle. The digested tissue 
was then passed through a “filter-cartide” (falcon) in order to separate larger tissue pieces. 
The filtrate was centrifuged at 400xg at 4°C for 7-10 minutes. The pellet was then 
resuspended with erythrocyte lysis buffer and centrifuged again and resuspended in FACS-
PBS (5% FCS in PBS) for analysis. Total cell counts of cell pellets were performed by 
Neubaur hemocytometer.  
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2.2.1.4. Preparation of lung tissue lysates 
After isolation of mouse lungs, the lung tissue was cut into tiny pieces and distributed into 
two lysing matrix D tubes, one of which contained 500µl RIPA buffer without SDS for 
protein lysates, while the other tube contain 1000 µl Trizol reagent for RT-PCR lysates. The 
obtained samples were stored in -80 °C until use. 
 
2.2.1.5. Isolation of peritoneal murine macrophages 
For in vitro experiments, abdominal viscera macrophages were obtained from mice that have 
been injected intraperitoneally (i.p.) 3 days before with 1 ml of 4% starch solution in PBS (for 
accumulation of the macrophages in abdominal cavity). The macrophages were washed out 
from abdominal cavity of euthanizes mice with 5 ml of sterile PBS and centrifuged at 1200 
rpm at 4°C for 5 min. The cells were washed two times with PBS by centrifugation, 
resuspended in DMEM with 2% fetal calf serum (FCS) and 50 µg/ml gentamicin and adjusted 
to a concentration of 1*106 macrophages/ml and 2 ml of the cell suspension were plated into 
6-well dishes and incubated for 3-4 h at 37°C in a humidified incubator under 5% CO2. Non-
adherent cells were then removed by washing the dishes twice with PBS and the remained 
macrophages were stimulated with different stimulator reagents.  
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2.2.2. Tissue culture and cells methods 
2.2.2.1. Tissue cell culture 
2.2.2.1.1. General culturing of eukaryotic cells  
The mammalian cell lines were placed into media shown below and grown in disposable 
culture flasks or petri-dishes at 37 °C and 5% CO2. All cells were regularly split before or 
upon reaching confluency. For this purpose, the medium was aspirated and the cells were 
washed once with PBS and incubated with trypsin-EDTA solution (1 ml per 75 cm2 dish) at 
37 °C for about two to five minutes. When the cells had become detached, they were 
resuspended infresh serum-containing medium, counted and depending on the experimental 
design cultivated further in appropriate media. 
For determination of cell amounts, the cell suspension was diluted 1:1 with trypan blue 
solution and the number of cells was counted under light microscopy using Neubauer 
hemocytometer.  
cell line cultur medium  additives 
HEK209 D-MEM high glucose  10% FCS, Pen/Strep 
HeLa D-MEM high glucose 10% FCS, Pen/Strep 
Machrophages  D-MEM high glucose 2% FCS, Pen/Strep 
Murine fibroblasts D-MEM high glucose  10% FCS, Pen/Strep  
 
2.2.2.1.2. Freezing and thawing of eukaryotic cells 
To store cells for longer time, aliquots were frozen in liquid nitrogen (-181 °C). To prepare 
the cells for storage, they were grown in T175 flask or 10 cm dishes to 100% confluence and 
the cells were detached with trypsin-EDTA and centrifuged at 1200 rpm for five minutes. 
They were then resuspended in freezing medium (4 ml for a 10 cm dish) and 1ml of the 
suspension was distributed into cryotubes. These were kept overnight in polystyrene boxes at 
-70 °C to cool down the cells slowly and then transferred into liquid nitrogen tank, where they 
were stored. 
The so-frozen cells were thawed, if needed, in a 37 °C water bath and then pipetted into a ten-
fold excess of culture medium. To remove the DMSO, the suspension was centrifuged (1200 
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rpm, five minutes) and placed into the respective cell culture medium and cultured in an 
incubator. Fresh medium was added on the next day. 
 
2.2.2.1.3. Transfection and stimulation of eukaryotic cells 
 
Transfection of peritoneal machrophages with plasmid DNA 
Transfection of expression plasmids into peritoneal mouse macrophages was performed with 
Amaxa apparatus and the Amaxa mouse Machrophage Nucleofector kit (Lonza, Cologne) 
according to the manufacturer's instructions. For each transfection set 1*106cells were used. 
After transfection, the cells were incubated for 2-3 hours at 37 °C and 5% CO2. Then the 
medium was changed and the cells optionally stimulated with lipopolysaccharide (1µg/ml) or 
BLM (15U/ml) and mouse lung tissue lysate (contains carbohydrate) for additional 24 h. 
 
Stimulation of peritoneal murine macrophages 
After isolation of peritoneal mouse macrophages, as described in section (2.2.1.5), these cells 
were stimulated with lipopolysaccharide (1µg/ml) or BLM (15U/ml) and mouse lung tissue 
lysate (contains carbohydrate) for 24 h.  
To obtained the lung lysate that was used for macrophage stimulation, lungs from two WT 
mice were minced, placed into 5 ml of PBS, 4 times repeatedly frozen in liquid nitrogen and 
thawed at 37°C water bath, sonified on ice for 30 second three times and centrifuged. The 
supernatant was filtered sterile and used for stimulation of macrophages in a dilution of 1:100. 
The optimal dilution was estimated in preliminary experiments. The lung lysate was used as a 
source of released endogenous damage-associated molecular pattern molecules. 
 
Transfection of eukaryotic cells with PEI 
For transfection of RNA or plasmid DNA into eukaryotic cells, different transfection 
strategies were applied. For efficient transfection of eukaryotic cells (e.g. HEK209, HeLa and 
fibroblasts) the transfection reagent polyethylenimine (PEI) was used. The cells were seeded 
at a 50% confluence the day before the experiment. On the day of trasfection, growth medium 
49 
PhD thesis Abdulaleem Alnajar 
was replaced by transfection medium (without penicillin/streptomycin). For a 35mm dish (6-
well) a mixture of 10µl PEI and 200µl OPTI-MEM was incubated for 5 minutes at room 
temperature before adding DNA. The PEI-mixture and DNA were incubated for 15 minutes at 
room temperature and then added to the cells. The cells were incubated with the transfection 
mix for different times depending on the experimental schedule.  
 
FHL2 knockdown by siRNA 
For suppression of the cellular FHL2 expression, fibroblasts were treated with "small 
interfering RNA (siRNA). Transfection of fibroblasts with FHL2-specific siRNA (Eurofins 
MWG Operon, Germany) was performed using the HiPerFect transfection kit (Qiagen, 
Cologne) according to manufacturer's instructions (end concentration: 2-5 nM siRNA). After 
24 hours, the cells were lysed and used for analysis. As a control, so-called "scrambled" 
siRNA (2-5 nM siRNA) was used. 
 
2.2.2.2. Flow cytometry assay (FACS analysis) 
The prepared BAL fluid cells or tissue cells described in section (2.2.1.3) were stained with 
different fluorochrome-labeled antibodies for FACS analysis (Table 7). 
The cells were count and at least 2*106 cells for each sample were distributed into 1.5 ml 
FACS tubes for staining. Usually controls including unstained cells were included. The cells 
were centrifuged at 400xg for 5-10 min at 4C° and after pouring off the liquid the tubes were 
inverted on a paper towel. The cell pellets were resuspended in 50 µl staining solution 
(contains fluorochrome-conjugated secondary antibodies) and incubated for 17 min on ice. 
For the remaining 3 min of incubation, the 7AAD dye (for dead cells) was added with 50 µl 
per batch. After 20 min (total incubation), the cells were again pelleted and then taken up in 
50-500 µl FACS-PBS. The cells were than ready for FACS analysis. 
 
Marker-dye                  FACS channel Marker-dye                  FACS channel 
FITC FL1 PI  FL3 
PE                           FL2 APC                   FL4 
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2.2.3. DNA/RNA methods 
2.2.3.1. Transformation and isolation of plasmid-DNA from bacteria 
Chemically competent E.coli was transformed with a plasmid using the heat-shock method. 
For the transformation, the corresponding plasmid DNA (1µg) was mixed with 100µl of a 
suspension of heat shock competent bacteria and incubated for 20 minutes on ice. Then a heat 
shock at 42 °C for 45 seconds was performed and the bacteria were cooled on ice and 
cultivated at 37 °C in 500µl LB medium without ampicillin but with shaking for one hour and 
then plated on agar plates with appropriate antibiotics. On next day, individual bacterial 
colonies were picked and cultured in 4 mL of LB medium with antibiotic for 12 hours. From 
these pre-cultures, cells were then transferred to 150ml of LB medium with ampicillin (100 
µg /ml) and cultivated overnight. 
The obtained cell suspension was centrifuged and the plasmid DNA was isolated using the 
QIA filter plasmid maxi kit (Qiagen, Hilden, Germany) according to manufacturer’s 
instructions. This kit is based on the method originally published by Birnboim and Doly 
(Birnboim and Doly 1979). 
 
2.2.3.2. Isolation of RNA from cells and tissue 
 
By using the Qiagen RNeasy® Mini kit: 
In order to determine the transcript amounts of certain genes by real-time quantitative reverse 
transcription PCR, RNA had to be isolated from cells or tissues. The Qiagen RNeasy® Mini 
kit was used according to manufacturer’s recommendations for isolaton of total RNA from 
animal cells or animal tissue. For experiments with eukaryotic cells, the cells were cultured in 
6cm dishes or 35mm dishes (6-well dishes). Cells were washed with PBS and lysed with 
600µl/6cm dish or 350µl/35mm dish RLT buffer containing β-mecaptoethanol. The samples 
were homogenized and mixed with 1:1 (v/v) 70% ethanol and applied on spin columms, 
washed and eluted with RNase-free water. Then the RNA was stored at -80°C. 
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By using TRIZOL Reagent: 
Total RNA was isolated from lung tissue by using the Trizol reagent according to the 
manufacturer's protocol. Briefly, the lung tissue, described in section (2.2.1.4) was 
homogenized using the Ultra-Turrax Homogeniser Type T8 (IKA-Werke, Staufen, Germany) 
and mixed with Trizol lysis solution and incubated for 5 min at room temperature. RNA was 
then recovered from the lysate by adding 200 μl chloroform (Sigma) followed by 
centrifugation at 9000 rpm for 20 min at 4 °C. The aqueous layer was then transferred into a 
clean microcentrifuge tube. RNA was precipitated by adding isopropanol and pelleted by 
centrifugation at 9000 rpm for 20 min at 4 °C. The pellet was dissolved in 300 μl Na acetate 
(0.3 M & pH 5.2) and 300 μl phenols (pH 4.1-5.6) was added and centrifuged for 5 min at 4 
°C and at 13000 rpm. Equal volume (1:1) of chloroform was added into the aqueous phase 
and again centerfuged. 1.5 ml of cold 96% ethanol was added to the aqueous phase of the 
probe, mixed, placed for 30 sec into liquid N2 and centrifuged again for 20 min. The pellet 
was washed with 80% ethanol, air dried, and resuspended in 30-50 μl RNase-free water and 
stored at -70°C until using. 
 
2.2.3.3. cDNA synthesis 
After determination of the RNA concentration by the NanoDrop spectrophotometer; equal 
amounts of total RNA were reverse-transcribed using a High-Capacity cDNA Reverse 
Transcription Kit (ABI 4368814) according to the manufacturer’s recommendations. For 
example, 25µl of total RNA with defined concentration were mixed with 25µl Master Mix 
cDNA kit (10x RT Random Primers, 10x RT Buffer, 25x dNTPs MIX (Stock 100mM), 
RNase Inhibitor, Reverse Transcriptase and d. H2O) in PCR-microtubes and after short 
vortexing and short centrifuging, the mixed samples were run in Thermocycler 
(N99nBiometra T Gradient) according to the program listed below and obtained cDNA 
samples were stored at -20°C. 
Programm of the Thermocycler:  
Heating Step1 Step2 Step3 Step4 
25C° 25C° - 10 min 37C°-120 min  85C° - 5 sec (1 min) 4C° 
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2.2.3.4. Real-Time quantitative Polymerase Chain Reaction (qRT-PCR)  
The polymerase chain reaction (PCR) is a method for exponential amplification of DNA by a 
thermo stable DNA-dependent DNA polymerase. This technique was further refined by the 
discovery of reverse transcriptases and the possible detection of PCR product amounts while 
the reaction is still in progress. Today, during the reaction (“real-time”) the amount of cDNA 
of certain transcripts (mRNA) can be quantified after reverse transcription either by using a 
specific fluorescence labeled reporter probe (Taqman technique) or by the incorporation of a 
fluorescence  dye (e.g. SYBR Green) into the amplified DNA double strand. 
 
Taqman-PCR: 
The cDNA samples were diluted 1:10 for TaqMan-PCR. For this technique aTaqMan®-
Meister Mix [4.4µl H2O, 0.2µl primer L (20µM), 0.2µl primer R (20µM), 0.2µl Taqman 
probe (20µM) and 10µl Master Mix (MM)] was used. 15 µl Master Mix and 5 µl template 
(cDNA sample) were pipetted in duplicate into a 96 well- RT-PCR plate. The RT-PCR plate 
was covered and centrifuged for 2 min at 1000 rpm at room temperature and subjected to the 
Taqman RT-PCR Cycler machine. The relative transcription levels of target and reference 
genes (Cytochrom C and GAPDH) were determined and an absolute quantification and a 
relative quantification were calculated by RT-PCR Cycler software. The particular steps of 
the qRT-PCR procedure are shown in Table 11. 
 
SYBR Green® PCR: 
For this technique the Brilliant II SYBR Green QPCR Master Mix was used for detection of 
amplified DNA. The Brilliant II SYBR Green QPCR Master Mix contained all qPCR relevant 
reagents: SYBR Green, Taq polymerase and dNTPS in the appropriate buffer. 4 µl of Brilliant 
III SYBR Green QPCR Master Mix and 0.2 µl  Reference Dye (33,3nM)  and 0.6 µl of 10 µg 
target gene specific primer (forward and reverse primer mix) were applied  per well (96-well 
plat). 0.5µl of each cDNA sample was diluted in 6.7 µl sterile H2O per well and added. Each 
sample was measured as doublet. The qRT-PCR was performed on the Roche light cycler 
480III under following conditions, as summarized in Table 11. 
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The increasing fluorescence was measured after each elongation step. The melting curve of 
PCR products at the end of the reaction was performed to determine the specificity of each 
target gene primer pair. The determination of the ct-values was carried out automatically by 
the PCR Cycler software. In addition to the transcription level of the genes of interest, the 
transcription levels of a housekeeping gene (GAPDH) were determined to eliminate 
differences in overall transcription levels caused by possible toxic effects of sample`s 
treatment. Therefore the 2-ΔΔct method was used (Livak & Schmittgen, 2001), and changes in 
amounts of transcripts were calculated as n-fold of the untreated control.  
 
Table 11: Thermal profile of RT-PCR: 
step temperature time 
activation of polymerase 95°C 10 min 
denaturation 95°C 30 s  * 
annealing 60°C 1 min * 
extension 72°C 1 min * 
denaturation 95°C 30 s 
melting curve 55°C - 95°C 10 min 
* 40 cycles 
 
2.2.3.3. Gene reporter assay (Luciferase assay) 
To study the activity of a promoter, it is possible to set the expression of a so called “reporter 
gene” (usually an enzyme) under the control of the promoter of interest. The activity of the 
promoter can then be measured directly by measuring the activity of the enzyme. A common 
reporter gene is the luciferase of photinus pyralis. The substrate of this enzyme is luciferin, 
which will be converted into oxyl-luciferin thereby emitting light. This emission can be 
detected by a luminometer (LB96V) and the activity is determined as relative light unit 
(RLU*s). For reporter gene assay, cells were grown in 12-well dish to 60% confluence and on 
next day transfected with appropriate plasmids. The transfection of a plasmid that carried the 
luciferin gene under the control of the promoter of interest was carried out as described earlier 
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using PEI (section 2.2.2.1.3). After 24 hours of transfection, the cells were lysed for at least 
30 minutes at 4C° with 150 µl luciferase harvest buffer. In a 96-well microtiter plate 50 µl of 
sample lysates were added to 50 µl luciferase assay buffer. The samples were then measured 
two seconds after addition of luciferin solution for the duration of 10 seconds. Relative light 
units (RLUs) were calculated in relation to protein amounts and data were plotted in 
GraphPad Prism diagrams. 
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2.2.4. Protein methods 
2.2.4.1. Preparation of protein samples from cells and tissue 
Preparation of protein lysates from cells 
Cell lysates were prepared by using different lysis buffers (TLB, RIPA or Harvesting buffer). 
The medium was aspirated and cells were washed with PBS. For a 6-well dish 200µl of lysis 
buffer were added and cells were incubated for 10-15 minutes at 4°C or in ice. Protein lysates 
were collected and centrifuged at 10000 rpm for 10 minutes at 4°C; supernatants were 
collected in a 1.5 ml tube and stored at -20°C.  
 
Preparation of protein lysates from tissue samples 
Tissue samples described in section (2.2.1.4) were mechanically minced on ice in RIPA-
Buffer using Ultra-Turrax Homogeniser Type T8 (IKA-Werke, Staufen, Germany). The 
lysates were frozen and thawed once before pelleting the debris by centrifugation at 13000 
rpm (4°C). Supernatants were collected and stored at -20 °C for downstream applications. 
 
2.2.4.2. Determination of protein amounts 
By using the Bradford reagent: 
The protein amounts were determened using Bradford reagent (BioRad protein assay solution, 
BioRad, Muenchen). 400µl of the 1:5 diluted stock solutions (with d. water) were incubated 
with 2 µl of lysate samples for 5 minutes at room temperature. In the presence of ethanol and 
phosphate acid, the absorption of Coomassie brilliant blue G250 is shifted from 465nm to 
595nm upon binding of proteins, which is used for determination of protein concentration, as 
the rising extinction is proportional to rising protein amount (Bradford 1976). To determine 
absolute protein concentrations different BSA solutions with defined protein concentrations 
were measured and these counts were used as calibration values. 
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By using the BCA Protein Assay Kit: 
Protein concentrations were determined with the BCA Protein Assay Kit (Pierce, Bonn, 
Germany) according to the manufactures instructions. Routinely, 20 µl of protein lysates were 
mixed with 400 µl of the working reagent of the kit that was diluted 1:50 as described in the 
product manual. After incubation of the mix at 37°C for 30 min the extinction levels of the 
samples were determined using the Bio Photometer (Eppendorf) with BSA-standard probes 
used for calculation of the calibration values. 
 
2.2.4.2. Sodium-Dodecyl-Sulfate gel electrophoresis (SDS-PAGE) 
Sodium-dodecyl-sulfate gel electrophoresis (SDS-PAGE) is an efficient method to separate 
heterogeneous protein samples by the means of electrophoresis according to their size 
(Laemmli 1970). The gel was poured between two glass plates (Bio-Rad apparatus) and this 
gel is formed by the monomers acrylamide and bis-acrylamide, which copolymerize in the 
presence of APS and TEMED. The percentage of acrylamide/bis-acrylamide in a gel solution 
determines the size of the pores. 
In a discontinuous SDS-PAGE the sample first enters the large pores of the stacking gel 
before entering the narrow pores of the resolving gel. The samples were mixed with 1:3 with 
sample buffer containing β-mercapto-ethanol and the anionic detergent SDS. The samples 
were heated at 95 °C for 5 minutes to denature the proteins. The β-mercapto-ethanol disrupts 
disulfide bonds between cysteine residues and SDS coats the protein molecules with a 
negative charge, thereby destroying the secondary, tertiary and quaternary structures of the 
proteins. The proteins have now all the same electrical charge and can be separated by their 
specific size. For every experiment, gels were prepared freshly. Separation of samples was 
done at 100-150V in 1x SDS running buffer. One line was loaded for a pre-stained protein 
marker.  
Separating gel 7 % 9 % 10 % 12.5 % 
Bis-acrylamide 2.2 ml 3 ml 3.3 ml 4.2 ml 
H2O 3.9 ml 3.1 ml 2.8 ml 1.9 ml 
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Add 3.7 µl Tris/HCL (PH 8.9), 50 µl SDS-solution (20%), 100 µl APS (10%) and 2 µl 
TEMED. 
Stacking gel: 7.15 ml Bis-acrylamide, 8.9 ml 1M Tris/HCL (PH 6.8), 33.2 ml distilled water 
and 250 µl SDS-solution (20%)  mix and keep at 4°C. 
Add fresh: 50 µl APS (10%) and 5 µl TEMED for 5 ml mix of the stacking solution. 
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2.2.5. Immunological methods 
2.2.5.1. Western blot (Immunoblot)  
Protein samples previously separated in a SDS-PAGE can be transferred to a solid membrane 
for further immunological analysis. In order to do that an electric field was applied to force 
the proteins to transfer through the gel and to be bound to the nitrocellulose membrane at the 
same geometrical arrangement. The protein migrates from the negative charged cathode to the 
positive charged anode. In all experiments the transfer was done under wet condition using a 
BioRad “tank blot chamber”. The blot was set up as follows: on both sides one sponge pad 
and two Whatman GB002 paper (Schleicher & Schuell, Dassel), in between the SDS-gel and 
nitrocellulose membrane (Schleicher & Schuell, Dassel). The nitrocellulose membrane was 
soaked in buffer before use. This “sandwich” was fitted in the chamber so that the membrane 
is directed to anode (+) and the SDS gel to cathode (-). The transfer was done at 400mA for 1 
hour in blotting buffer at room temperature. Once the transfer was finished the membrane was 
rinsed in TBS-T. Unspecific binding sites were saturated by blocking with 5% BSA or 5% 
low-fat milk in TBS-T buffer for a minimum of 30 minutes at room temperature or overnight 
at 4°C. BSA or low-fat milk was used as instructed by the manufactures of the antibodies. 
Incubation with primary antibodies was done on a shaker either overnight at 4°C or 1-2 hours 
at room temperatures. Before incubation with the secondary antibody, the membranes were 
washed with TBS-T three times for ten minutes. Incubation with the secondary antibody was 
carried out for 30 mints- 1 hour at room temperature, followed by washing three times for ten 
minutes.  
All antibodies were obtained from animal sources; the secondary antibodies were raised 
against the constant region of the target specific primary antibodies. 
Detection of specific bands was done by incubation of the membrane with 
chemiluminescence substrate (ECL detection reagent) for one minute. Specific bands were 
visualized by using the digital detection system Stella with AIDA Image Analyzer software 
(Raytest Isotopenmeßgerate GmbH, Straubenhardt, Germany).  
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If the blot was analyzed with multiple antibodies, the antibodies of the first staining were 
removed after ECL detection. The membrane was swirled a half hour at 60 °C in stripping 
buffer and washed for one hour in water or TBST and finally blocked for one hour in 3% law-
fat milk powder in TBST. 
 
2.2.5.1. Sircol-assay 
The Sircol Assay is a dye-binding method designed for the analysis of total (acid and pepsin-
soluble) collagens. This assay can assess the rate of newly synthesized collagen produced 
during periods of rapid growth and development. New collagen is also generated during 
inflammation, wound healing and development of fibrosis. To detect the production rate of 
collagens, the Sircol Soluble COLLAGEN Assay kit was used according to the 
manufacturer's instructions. Briefly, 50 µl from the prepared BALF described in section 
(2.2.1.3) were used and Sirius red reagent was added to each sample and mixed for 30 min. 
The collagen–dye complex was precipitated and separated by centrifugation at 12,000g for 10 
min, and dissolved in alkali reagent. Finally, the samples were loaded into a microtiterplate 
reader and the absorbance was determined at 555 nm. 
 
2.2.5.3. Immunohistochemistry (IHC)  
Immunohistochemistry (IHC) combines anatomical, immunological and biochemical 
techniques to identify discrete tissue components by the interaction of target antigens with 
specific antibodies tagged with a visible label. IHC consists of the following steps: 1) primary 
antibody binds to specific antigen; 2) antibody-antigen complex is bound by a secondary, 
enzyme-conjugated, antibody; 3) in the presence of a substrate and a chromogen, the enzyme 
forms a colored deposit at the sites of antibody-antigen binding. 
For tissue staining by IHC, the tissue lung sections were deparaffinized and rehydrated by 
using histol and alcohol series. Antigens were retrieved by 5 min proteinase K digestion of 
samples at room temperature or by cooking the samples for 30 minutes in 10mM citrate 
buffer, pH 6.0 and cooling at room temperature or ice. The sections were treated with 3% 
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H2O2 for 10 min and then incubated with blocking buffer (0.1% Triton and 10% FCS in PBS) 
for 30 min, followed by incubation with specific target antibody (primary antibody) for 1h at 
room temperature or overnight at 4°C. After three washes by wash-block buffer, a 
biotinylated secondary antibody was applied for 30 minutes after which the samples were 
washed again with wash-block buffer. For the color reaction, the Vectastain ABC kit (Vector 
Laboratories / Linaris GmbH) was used according to manufacturer's instructions. The A and B 
solution (Vector Laboratories / Linaris GmbH) were added for 30 minutes with following 
washing with wash-block buffer. Finally, the sections were incubated in Red Alkaline 
Phosphatase Substrate solution (Vector Laboratories / Linaris GmbH) for 30 minutes at room 
temorature.  
After that, the stained sections were counterstained with haematoxylin and slides were 
dehydrated with graded series of alcohol (80%, 96%, 100% isopropanol), cleared in histol and 
mounted in Roti-Histol or Tissue-Tek Glas mounting medium and analyzed with digital 
camera microscopy. 
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2.2.6. Histological methods 
2.2.6.1. Fixation and paraffin embedding of lung tissue samples 
For histological analysis, mice lung tissues were fixed and embedded into paraffin. For this 
purpose, the tissue pieces were fixed in 4% paraformaldehyde (in PBS) in 15 ml falcon for 4-
6 h at room temperature. To remove the air from lung tissue, the tubes were placed into an 
exicator and vacuum was generated for about 20-30 min by using an air pump. This procedure 
was repeated until tissue pieces slided to the bottom of falcon tubes. Fixed tissues were 
washed two times with PBS before ascending the alcohol dehydrationseries (70%, 90%, 96% 
and 100% isopropanol). Then the tissue pieces were incubated in histol for 4 h at room 
temperature. Subsequently, the specimens were transferred to 60°C pure paraffin (the paraffin 
was changed several times, 1, 2 and 3 types of paraffin were used) and incubated for 6 h or 
for overnight (each type of paraffin). Finally, the samples were cast into paraffin blocks by 
using a tissue embedding machine (EG1150H, Leica, Germany) and then stored at 4 °C. 
For staining the lung tissue specimens were cut into 4mm thick sections using a microtome. 
 
2.2.6.2. Haematoxylin and Eosin (HE) & Trichrome staining 
Formalin fixed and paraffin-embedded murine lung tissue sections were routinely stained 
with haematoxylin and eosin (HE) stains and with AZAN- Trichrome stainaccording to 
Heidenhein. After deparaffinization of lung tissue sections by using histol, the sections were 
rehydrated for three minutes in an ascending alcohol series (100%, 96%, 90%, 80% and 70% 
isopropanol) and incubated with haemotoxylin for 4 minutes and differentiated in tap water 
for 10 minutes and then incubated with eosin for 5 minutes. Finally the sections were 
dehydrated with the alcohol series (80%, 96% and 100% isopropanol) and in histol-cleared. 
The section slides were then covered by cover slipsand Roti-Histol or Tissue-Tek Glas 
mounting medium and analyzed with digital camera microscopy. 
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2.2.6.3. Continuous numerical scale system 
A continuous numerical scale system was used for determining the degree of fibrosis in lung 
specimens (Ashcroft et al. 1988). The grading was scored on a scale from 0 to 8, using the 
average of microscope field scores, as in table 2. The system allows measuring the degree of 
fibrosis in small samples of tissue (1 cm) and can provide a detailed description of changes in 
the lung (Ashcroft et al. 1988).  
To score the degree of fibrosis, three-four fields of several sections of lung tissue were 
photographed, numbered and scored by 3-4 observers in a blinded fashion. The mean scoresof 
each observer for each lung were calculated and mean score value of all observers defined the 
degree of fibrosis for that particular lung.   
 
Table 12: Criteria for grading lung fibrosis (Ashcroft et al. 1988). 
Grade of fibrosis  Histologicalfeatures 
0-1 Normal lung 
1-2 Minimal fibrous thickening of alveolar or bronchiolar walls 
3-4 Moderate thickening of walls without obvious damage to lung 
architecture 
5-6 Increased fibrosis with definite damage to lung structure and 
formation of fibrous bands or small fibrous masses 
6-7 Severe distortion of structure and large fibrous areas; "honeycomb 
lung" is placed in this category 
8 Total fibrous obliteration of the field 
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2.2.7. Data analysis 
 
Data are expressed as the mean ± SEM or ± SD. Statistical analyses were performed with 
Graphpad Prism 4.02 software. Means between two groups were compared with 2- tailed 
unpaired Student’s T-test, Wilcoxon test or 2-way ANOVA. P < 0.05 was considered as 
statistically significant. 
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3. Results and Discussion 
3.1. Sensitivity of WT and FHL2KO mice to BLM treatment 
To analyse the potential role of FHL2 in development of lung fibrosis, WT and FHL2-
deficient mice were first treated with different doses of BLM to compare their sensitivity to 
the drug. Unexpectedly, the FHL2 knockout mice showed a higher mortality rate to BLM than 
WT mice. At 5 U/kg BLM almost 50% of FHL2-negative animals died during the first 10 
days of drug application, while the vast majority (89%) of WT mice survived the treatment 
(Figure 9A). A dose of 2 U/kg was toxic for 15% of FHL2KO mice but for none of WT mice 
and 100% of both WT and FHL2-KO mice survived the application of 1U/kg (Figure 9A). 
The higher sensitivity of FHL2-/- mice to the antibiotic was also reflected by the stronger 
loose and slower recovery of their body weight after a single application of lower BLM doses 
(Figure 9B). As result, FHL2 knockout mice are more severe affected upon BLM treatment 
compared with WT mice. 
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Figure 9: Sensitivity of FHL2WT and KO mice to BLM treatment. (A) The mice have received intranasally a 
single dose of BLM and were scored for mortality rate 10 days later. Cipher over columns show the number of 
analyzed animals. (B) Body weight alteration of FHL2WT and KO mice after a single intranasal application (2 
U/kg) of BLM. n= 5-6 for each time point. 
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3.2. Development of BLM-induced lung fibrosis 
BLM causes lung tissue damage at early steps after application and fibrosing of lung tissue at 
later steps. Fibrosis usually occurs when secretion and deposition of ECM proteins, primarily 
collagens, exceeds their degradation (Wynn 2011; Krieg et al. 2007). This might be a result of 
disturbed wound healing or chronic inflammation (Wynn 2011). To reveal whether the 
observed differences between WT and FHL2-KO mice also went along with dissimilar 
pulmonary aberrations and to clarify whether the pathology is of fibrotic nature or not, we 
performed a comparative histological analysis of WT and FHL2-deficient lungs at various 
time after BLM application. The H&E staining of lung sections showed a clear increase in 
swelling of alveoli and interstitial tissues as well as an accumulation of infiltrating cells in 
both WT and knockout lungs (Figure 10A). These alterations were transient and reached the 
maximum rate in both types of mice two weeks after BLM application, which is in agreement 
with published data showing that BLM-induced lung fibrosis in mice is severe but transient, 
which distinguishes the mouse BLM-mediated pulmonary fibrosis from that of humans (Hay 
et al. 1991; Walters & Kleeberger 2008). To reveal whether the expression and deposition of 
connective tissue is changed changed in mice after BLM injection, serial lung sections were 
stained with AZAN trichrome according to Heidenhein. The stains showed that the observed 
alterations were indeed accompanied in both WT and FHL2-null lungs with increased 
expression of extracellular matrix proteins, indicating that lung changes are mainly of fibrotic 
nature (Figure 10B). A further detailed mouse comparison showed that these changes arose in 
FHL2 knockout mice faster and decreased after reaching the peak at two weeks more slowly 
compared with WT mice. Quantification of lung fibrosis according to Ashcroft criteria 
(Asheroft et al. 1988) confirmed the difference in development of fibrosis between WT and 
knockout animals and further showed that the fibrotic changes are highly significant at early 
time of BLM application, but reach similar levels after two weeks and decline significantly 
faster in WT mice (Figure 10C). As fibrosis always goes along with alterations in collagen 
deposition, we compared their amount in WT and FHL2-KO lungs. Measuring collagen 
amounts in bronchoalveolar lavage fluids (BALF) by the Sircol Collagen Assay showed an 
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increase after BLM treatment in WT and in FHL2-/- mice as well, but the revealed differences 
were minimal (Figure 10D). A further unexpected observation made from these analyses was 
that lungs of non-treated control FHL2-/-mice already showed some fibrotic properties. 
Despite of a large variability between animals, FHL2 knockout lungs generally displayed a 
denser lung structure with a stronger expression of connective tissue in interstitial spaces 
(Figure 10B). Ashcroft values and amounts of Sircol measured collagens confirmed this 
observation and showed that the differences are significant (Figure 10E & F). 
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Figure 10: Development of BLM-induced lung fibrosis in FHL2 wild type and knockout mice. A&B, WT and 
FHL2-KO mice obtained a single intranasal application of BLM (2 U/kg) and the right lungs were fixed in PBS 
with 4% paraformaldehyde, embedded into paraffin and 4µ-thick sections were stained with Hematoxylin and 
eosin (A) or AZAN trichrome according to Heidenhain (B). Bar=200 µm. (C) Lung sections shown in A&B 
were scored for fibrotic alterations according to Ashcroft criteria (Ashcroft et al. 1988) by three observer in a 
blinded fashion. Lungs from four mice with at least four different sections per lung were analyzed for each time 
point. (D) The collagen amount in bronchoalveolar spaces of BLM treated mice (2 U/kg) was measured by 
Sircol Collagen Assay. The number of analyzed animals per time point varied from three to eight. Mean values ± 
SE are shown. (E&F) Lung fibrosis score and collagen content in BALF, respectively, of non-induced control 
mice are shown.  
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3.3. Expression of ECM proteins during BLM-induced lung fibrosis 
Fibrotic alterations are usually paired with excess expression of different extracellular matrix 
proteins. Therefore we compared alterations in ECM protein amounts in lungs of WT and 
FHL2 KO mice after BLM treatment by Western blot technique. As shown in Figure11A no 
significant differences in up-regulation of collagen type I, laminins (studied by expression of 
the laminin gamma-1 chain), fibronectin or α-smooth muscle actin were detected. Also 
collagen type III, the major profibrotic protein, showed only minor differences between FHL2 
WT and KO lungs. However, tenascin C (TNC) showed a stronger and long-lasting induction 
in FHL2 knockout lungs, which could also be confirmed by immunohistochemistry 
(Figure11B). All together, these data are in good consistency with the histological and Sircol 
analysis (Figure 10). They confirmed that connective tissue proteins are induced in lungs of 
both FHL2 WT and KO mice and that there are only minor differences between them, with a 
slight trend to a stronger induction in FHL2 knockout lungs. The acute lung inflammation 
plays an important role in the development of BLM-induced lung fibrosis (Shaw & Martin 
2009; Wynn 2011). During the acute inflammation phase many changes occur, in first line 
expression and secretion of inflammatory molecules takes place. TNC is a matrix protein that 
is always up-regulated in response to inflammation and tissue remodelling (Tucker et al. 
2009). Its expression kinetic in FHL2 knockout lungs assume a stronger ongoing 
inflammation at early stages of BLM treatment and a slower ceasing of inflammatory and 
tissue damaging processes in later stages. 
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Figure 11: ECM protein expression. (A) FHL2WT and knockout mice have been instilled intranasal with BLM 
(2 U/kg) for indicated times. The left lung was then lysed with RIPA buffer and 20 µg of total lysates were 
analyzed by Western blotting for expression of different proteins. Lung lysates from three animals per each time 
point were studied. Equal protein loads were verified by -actin immunoblotting. (B) Paraffin lung sections of 
control and BLM-induced (for 10 days) were stained for tenascin C (red). Nuclei (blue) were counterstained with 
hematoxylin. Bar=500 µm. 
 
3.4. FHL2 inhibits expression of tenascin C 
To define whether FHL2 regulates the expression of the proinflammatoryTNC protein, we 
knocked down the FHL2 in mouse fibroblasts that spontaneously express high levels of TNC 
and could show that this leads to increase in TNC transcripts (Figure 12A). Further, FHL2 
strongly inhibited the TNC promoter activity in different cell lines when it was co-expressed 
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with a reporter gene construct containing the tenascin C promoter sequence in front of a 
luciferase gene and, the complete FHL2 protein was needed for an efficient inhibition, as our 
N-terminal and C-terminal truncation analysis of the human FHL2 protein showed (Figure 
12B-D). As result, FHL2 reduces the expression of TNC via inhibition of its transcriptional 
level. 
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Figure 12: Effect of FHL2 on expression of tenascin C. (A) Immortalized embryonal fibroblasts from C57Bl/6 
mice was transfected with scrambled or FHL2 specific siRNA for 24 h and the expression of FHL2 and tenascin 
C was analyzed by TaqManqRT-PCR. (B) HEK 293 cells were transfected for 30 h with a luciferase reporter 
gene construct containing a 2000 bp long tenascin C promoter sequence and plasmids containing either the 
empty vector, the full-length [1/2-4], the C- [1/2-2] or N- [3-4] terminal truncation mutants of human FHL2 and 
the luciferase activity was measured. (C and D) The dependency of the TNC promoter activity on expression of 
FHL2 was also studied in HeLa cell and embryonal fibroblast from WT mice. As in (B) a luciferase reporter 
gene construct containing the tenascin C promoter sequence and plasmids containing either the empty vector or 
the full-length of FHL2 were cotransfected in these cells. Relative scores are presented. Mean values ± SD are 
shown. 
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3.5. FHL2-deficient mice have a higher inflammation status in lungs 
The alarmins S100A8 and S100A9 are calcium-binding proteins that belong to the damage-
associated molecular pattern proteins and are released by neutrophils and macrophages very 
early during inflammation. They are increasingly used as biomarkers for ongoing 
inflammatory processes (Chan et al. 2012). Our results indicate a higher inflammation state in 
lungs of FHL2-KO than inWT animals on BLM induction. Therefore, we measured the extent 
of the S100A8/A9 heterodimer protein in bronchoalveolar fluid. Its amount was indeed 
permanently higher in FHL2-/- mice (Figure 13A) and interestingly, non-stimulated control 
FHL2-/-mice already contained significantly higher levels of the S100A8/A9 proteins in the 
BALF and in serum as well (Figure 13B). Neutrophils are not only the major source of the 
S100A8/A9 alarmin, but also are the cells that infiltrate as first the inflamed or injured tissue, 
where they release the S100A8/A9 protein complex that acts then as a proinflammatory 
cytokine (Burns et al. 2003; Vogl et al. 2008). Staining of lung sections for S100A9 showed 
in WT lungs the number of S100A9-positive neutrophils grew rapidly after BLM instillation, 
reaching a peak at day 14 and declining afterwards, thus resembling the fibrotic kinetic shown 
in Figure 13D. However, control FHL2-deficient mice already contained a significantly 
higher number of S100A9-expressing cells than WT lungs did, and their number did not 
increase but rather decreased after BLM application shown in Figure 10. Thus, the knockout 
mice seem to have a disturbed inflammation process. During inflammation many pro-
inflammatory and pro-fibrotic cytokines are secreated by damage dresident and infiltrated and 
immune cells (Wynn 2011). Especially TGFβ and TNFα seem to play an importent role 
during both inflammation and fibrosis, with TGF-β being the major profibrotic cytokine and 
activator of myofibroblasts (Krieg et al. 2007). Therefore we measured the levels of these 
cytokines in BLM-injured lungs by qRT-PCR. These experiments showed that control FHL2-
KO lungs already contained higher levels of TGFβ mRNA than the lungs of WT control mice 
but on BLM induction the amounts of TGFβ were equalized (Figure14A). To the contrary, 
TNFα amounts did not show differences in control mice but on BLM application WT lungs 
expressed higher levels of this cytokine than FHL2-KO lungs. It is intriguing to speculate that 
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the higher expression of TGFβ in control FHL2-KO compared with control WT lungs is 
probably responsible for the more dense, almost fibrotic, lung structure of knockout mice as 
well as for the increased expression of S100A8/A9 in these mice. It is known that during an 
immune response, TGFβ promotes the recruitment and activation of neutrophils, the source of 
S100A8/A9 (Yang et al. 2010). Further, TGFβ regulates the production of S100A8 and 
S100A9, at least in the distant premetastatic lungs of tumor-bearing mice (Hiratsuka et al. 
2006). 
Given that absence of FHL2 facilitates a higher inflammation state and that the BLM-
mediated development of lung fibrosis is driven by acute pulmonary inflammation due to high 
destruction of lung tissue, it is conceivable that the amount of FHL2 in WT lungs will 
decrease during lung fibrosis. Indeed, both qRT-PCR and Western blot analysis of FHL2 
expression showed that it was down-regulated during the early destructive stage of BLM-
treatment but increased again at later stages (Figure 15A-B). The pro-fibrotic cytokine TGFβ 
induces FHL2 expression, while the pro-inflammatory cytokine TNFα down-regulates it 
(Muller et al. 2002; Joos et al. 2008). And, the kinetic of FHL2 down-regulation upon BLM 
treatment reflects very well the up-regulation of TNFα, indicating a possible causality 
between these two events (Figure 14B and 15). Taken together, our data indicate that the 
more severe lung phenotype observed in FHL2-deficient mice is probably based on the 
stronger induction of inflammation at early stages of BLM application. Remarkable is that in 
WT mice the FHL2 is down-regulated at this time and its expression increase again when the 
acute inflammation/destruction phase passed on to tissue regenerative phase. 
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Figure 13: S100A8/A9 expression in FHL2 WT and KO mice. (A) The content of S100A8/A9 protein complex 
was measured in BALF by ELISA. The number of analyzed animals per time point varied from 3 to 8. (B) 
Concentration of S100A8/A9 proteins in serum of control mice measured by ELISA. (C) Paraffin lung sections 
of control and BLM-induced (7 days) mice were stained for S100A9 (red). Bar=250 µm. (D) Quantification of 
S100A9-positive cells shown in C. The S100A9-positive cells were counted in five microscopic fields of a size 
of 0.75 mm2 for each lung sample. Lungs of four mice with at least four different sections per lung were 
analyzed for each time point. 
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Figure 14: The expression of pro-fibrotic (A) and pro-inflammatory (B) cytokines in FHL2 WT and KO 
miceafter BLM treatment. The lung lysates of WT mice and FHL2KO mice treated with 2U/kg BLM were 
analyzed by RT-PCR. Lungs of 5-6 mice were used per each time point. Mean values ± SE are shown. 
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Figure 15: FHL2 expression after BLM treatment. (A) FHL2 transcripts in lungs of BLM-treated mice were 
estimated by TaqManqRT-PCR. (B) Western Blot analysis of FHL2 expression in lungs of WT mice after BLM-
treatment (2U/kg). (C) Quantification of images shown in B. The FHL2 amount was estimated densitometrically 
as the relative intensity of the FHL2 bands to the loading controls. Values at time point 0 were taken as unity. 
The number of animals analyzed per time point varied from 6 to 12. Mean values ± SD are shown. 
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3.6. Immune status of bleomycin-treated lungs  
To study changes in the immune response to BLM-mediated lung tissue injury, single cell 
suspension of WT and FHL2-KO lungs were analysed by flow cytometry. In control mice, no 
significant differences in number of immune cells present in lungs of the two mouse types 
were seen (Figure 16A). On BLM administration the number of immune cells that 
extravagated into lungs increased as already published (Walters & Kleeberger 2008) but 
again, no differences between WT and FHL2-KO mice could be measured for all analysed 
types of immune cells except for macrophages. A slight but significant lower number of 
F4/80-positive cells were measured in FHL2-KO compared with WT lungs (Figure 16B), 
suggesting that absence of the FHL2 protein either impairs macrophage migration into injured 
lung or their activation in response to BLM-induced tissue damage. Immunohistochemical 
analysis of lung sections confirmed the increase of immune cell infiltration into BLM-injured 
lungs and showed in accordance with flow cytometry data that no difference in T-lymphocyte 
content between WT and KO lungs could be detected (Figure 16C). However the 
macrophages abundance was much more pregnant in WT compared with FHL2-KO lungs 
(Figure 16D), which confirms again the results of the flow cytometry analysis. Interestingly, 
the amount of B-lymphocytes was in contrary increased in FHL2 knockout treated lungs in 
comparison to WT lungs (Figure 16E). Lymphocytes migrate into inflamed or injured later 
into the site of injury. The high infiltration of B-lymphocytes into FHL2 knockout lungs 
probably supports the inflammatory process. Indeed, the role of B-lymphocytes in 
development of pulmonary fibrosis is already well documented. Injection of anti-B-
lymphocyte antibodies results in decreased fibrosis and mice with defective B-lymphocytes 
develop only mild forms of lung fibrosis (Yoshizaki et al. 2008). The depletion of B cells in 
the tight-skin mouse model for systemic sclerosis results in reducing of skin fibrosis and 
autoimmune response (Hasegawa et al. 2006). Our data showing that FHL2 deficiency results 
in a strong B-lymphocyte infiltration into BLM-injured and fibrotic lung raises of course the 
question, how FHL2 regulates B-lymphocyte infiltration into or proliferation in the inflamed 
lung. This, however, is atopic for future studies. 
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Figure 16: Immune cell infiltration into BLM-treated lungs of WT and FHL2KO mice. Single cell suspensions 
of lung tissue from control (A) or 8 days long BLM-stimulated (B) mice were studied for indicated surface 
receptors by flow cytometry. A total of 105 lung cells were analyzed and percentages of positively-stained cells 
are shown. n= 4-6 mice for each time point. (C-E) Paraffin sections from control and BLM-induced (for 10 
days) mice were stained with specific antibodies to T-lymphocytes (C; CD3), to macrophages (D; F4/80) or B-
lymphocytes (E; CD3). Immune cells are shown in red, while all nuclei (blue) were counterstained with 
hematoxline. 4-5 lungs were used in each case. 
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3.7. Macrophages activation during BLM-induce lung fibrosis 
The macrophages migrate into damaged tissue and play different roles in inhibition and 
resolution of the lung inflammation and fibrosis. They induce myofibroblast apoptosis, 
clearance of alveolar oedema fluid and they remove dead cells. Further, activated 
macrophages secrete different cytokines, such as TNFα or IL-6 that that have an important 
role in regulation of inflammation (Herold et al. 2011; Wynn 2011). Also, MHCII molecule is 
expressed on the surface of macrophages and a lack of this protein expression lead to severe 
immune-deficiency (Mach et al. 1996). Phenotype analysis of the immigrated macrophages 
showed that FHL2-deficient cells failed to be activated, as they expressed only low amounts 
of MHCII receptors as well as TNFα and IL-6 cytokines (Figure 17). This clears that, low 
infiltration of FHL2KO macrophages into lung tissue damage lead to low activation of these 
cells. 
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Figure 17: Activation of macrophages in bleomycin-treated lungs of FHL2 WT and KO mice. Single cell 
suspensions of lung tissue from control or 10 days BLM-stimulated mice were studied by flow cytometry. A 
total of 105 lung cells were analyzed and percentages of positively-stained cells are shown. The F4/80-positive 
macrophages were analyzed for expression of activation markers, the MHC-II receptor and the intracellular 
TNFα and IL-6 proteins. 
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3.8. FHL2 deficiency abrogates DC-SIGN-mediated activation of 
macrophages 
To study whether absence of FHL2 inhibits the activation of macrophages in general or the 
observed effect was specific for BLM-induced lung damage only, we isolated peritoneal 
macrophages from WT and FHL2-KO mice, stimulated them in vitro with lipopolysaccharide 
(LPS) or with BLM plus lung lysate and analysed them for activation markers. The latter 
stimuli should imitate the situation in the lung after BLM application (the high lung tissue 
damage). As data of Figure 18A and B show, activation of FHL2 knockout macrophages was 
not disabled when they were stimulated with LPS, but was prevented on stimulation with lung 
lysate and BLM. LPS is known to stimulate macrophages via binding the TLR4 receptor 
(Vogl et al. 2008). On lung tissue damage, however, large amounts of carbohydrates are 
released, which may activate macrophages via the CD209a (DC-SIGN) receptor (Van den 
Berg et al. 2012). qRT-PCR analysis of CD209a transcripts showed only a marginal 
expression in non-activated WT and KO macrophages and its amount was not changed on 
LPS stimulation. However, when cells were incubated with lung lysate and BLM, the 
transcription of CD209a increased dramatically, but only in WT macrophages (Figure 17C). 
Lung analysis also confirmed the negligible expression of CD209a in FHL2-/- mice, which 
did not change after BLM treatment (Figure 18D), suggesting that FHL2 is probably involved 
in the transcriptional regulation of CD209a. To test this, peritoneal macrophages from FHL2 
knockout mice were transfected with a plasmid containing cDNA for human FHL2 and 
stimulated with LPS or lung lysate plus BLM.Analysis of their phenotype showed that 
expression of recombinant FHL2, but not the empty vector rescued the transcriptional 
activation of CD209a on stimulation with carbohydrate-reach lung lysate. As expected, rescue 
of FHL2 had no influence on LPS mediated activation of FHL2-KO macrophages but 
significantly improved the macrophage activation on lung lysate and BLM stimulation 
(Figure 19A-D). 
 
80 
PhD thesis Abdulaleem Alnajar 
TNF
re
la
tiv
e 
ex
pr
es
si
on
control LPS BLM+LL
0
2
4
6
8
*
A IL-6
re
la
tiv
e 
ex
pr
es
si
on
control LPS BLM+LL
0
5
10
15
WT
FHL2KO
*
B
 
CD209a
re
la
tiv
e 
ex
pr
es
si
on
control LPS BLM+LL
0
5
10
15
20
25
WT
FHL2KO
***
C
CD209a
[days]
re
la
tiv
e 
ex
pr
es
si
on
0 5 10
0
5
10
15
20
D
 
Figure 18: FHL2 deficiency abrogates DC-SIGN-mediated activation of macrophages. (A-C) FHL2 WT or 
knockout mice were injected i.p. with 0.8 ml of 4% starch in PBS and three days later peritoneal macrophages 
were isolated, plated into 6-well plate dishes and stimulated with LPS (1µg/ml) or BLM (15U/ml) plus mouse 
lung tissue lysate for 24 h. After isolation of total RNA, the transcripts of indicated genes were determined by 
TaqManqRT-PCR. Mean values of three repeated experiments ± SD are shown. (D) The mRNA levels for 
DC209a in lungs of WT and FHL2-KO mice were determined by qRT-PCR (n=4-5 per case). 
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Figure 19: Rescue of FHL2 in FHL2-deficient macrophages restores their ability to up-regulate the CD209a 
receptor and to respond to BLM and lung lysate. Peritoneal macrophages from FHL2-KO mice were transfected 
with empty vector or human FHL2 cDNA, stimulated with LPS or BLM plus mouse lung lysate (LL) and 
analyzed for expression of human FHL2 (A) and for endogenous mouse CD209a (B), TNFα (C) and IL-6 (D) by 
TaqManqRT-PCR. Mean values ± SD are shown. 
 
3.9. FHL2 enhances macrophages MMP-12 expression 
Macrophages abundantly infiltrate the damaged tissue at early stages of wound healing and 
replace the neutrophils that migrate into injured tissue first. The macrophages not only 
remove the injured tissue debris but also play an important role in ceasing the inflammation 
and the initiation of regenerative processes by releasing cytokine- and chemokine-blunting 
proteases and other MMPs, such as MMP-12 (Dean et al. 2008; Yoshizaki et al. 2008). The 
macrophage-specific MMP-12 protease is extracellular enzyme know as an important 
mediator of inflammation. MMP-12 not only degrades extracellular matrix proteins, but also 
regulates the recruitment of inflammatory cells and cleaves many pro-inflammatory cytokines 
and chemokines, which results in reducing of inflammation and consequently of fibrosis as 
well (Dean et al. 2008; Masashi & Kenji 2008). Our data show that expression of MMP-12 is 
increased after BLM treatment in both types of mice, but the degree of induction is lower in 
lungs of FHL2-KO mice (Figure 20A) compared with WT lungs. Also, immunohistochemical 
staining of lung sections with anti-MMP-12 specific antibodies and quantification of these 
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stains by means of morphometry revealed an increase of the staining intensity with time of 
BLM treatment but to a lower degree in FHL2-KO samples (Figure 20B &C). Of note, the 
reduced expression of MMP-12 in FHL2 deficient mice correlated with the lower amount of 
activated macrophages in the lung (Figure 17). An additional question of future study is how 
FHL2 regulates the expression of the macrophage-specific MMP-12 enzyme. 
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Figure 20: The expression of macrophage MMP-12 after BLM treatment. (A) Lung lysates of FHL2WT and KO 
mice after 10 days of 5U/kg BLM treatment were analyzed by RT-PCR to show the expression of MMP-12 (n= 
4 mice for time point). (B) Paraffin lung sections of control and 2U/kg BLM-induced (7, 14 & 21 days) mice 
were stained for MMP-12 (red). Bar=250 µm. (C) quantification of MMP-12 expression shown in B. The MMP-
12 expression was analyzed in five microscopic fields of a size of 0.75 mm2 for each lung sample. Lungs of four 
mice with at least four different sections per lung were analyzed for each time point. 
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3.10. Macrophage depletion aggravates lung fibrosis 
Finally, we wished to test to what extent the inadequate amount of activated macrophages in 
lungs of FHL2-deficient mice accounted for the observed rapid fibrotic changes. Therefore 
the macrophage pools of WT and FHL2-knockout mice were depleted by injection of 
clodronate-liposomes and lung fibrosis was scored after BLM application (Figure 21). 
Ashcroft criteria revealed a significant increase in lung fibrosis after macrophage depletion in 
lungs of both WT and FHL2-knockout mice but to a similar degree, showing thus that 
successful activation and recruitment of macrophages into injured lung is needed to 
circumvent fibrotic changes. Interestingly, the enhanced fibrotic alterations in clodronate-
terated mice went along with increased accumulation of collagens in BALF and increased 
amounts of T-lymphocytes that infiltrate the lungs, but no difference between WT and FHL2-
KO mice were registrered, which is in good agreement with observed aggravation but 
disappearance of differences between mice lines in the severity of fibrosis. Remarkable also is 
that the levels of MMP-12 mRNA did not differ any more between WT and FHL2-KO mice 
and the total amount was decreased and reached the level of untreated FHL2 knockout lungs, 
additionally underlying the importance of MMP-12 up-regulation for the resolution of tissue 
damage. 
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Figure 21: Depletion of macrophages aggravates lung fibrosis. FHL2 WT and KO mice were injected i.v. with 
100µl/mouse of PBS- or clodronate-liposomes. On the next day they repeatedly received 75 µl/mouse of the 
same solution but intranasal. On the following day, the mice obtained 3U/kg of BLM intranasal and 5 days later, 
they had received again a dose of PBS- or clodronate-liposomes mixture intranasal. On day 10 after BLM 
application the lungs were fixed, embedded into paraffin and analysed for the presence of macrophages and T-
lymphocytes by immunohistochemistry using the anti-F4/80 and Cd3 antibodies, respectively, (A and B) and for 
fibrotic alterations (C and D), whereby the image of the panel C represents a H&E staining and the panel D the 
quantification of fibrotic alterations according to Ashcroft criteria. The F4/80- and CD3-positive cells were 
counted in five microscopic fields of a size of 0.75 mm2 for each lung sample. (E) The collagen amount in 
BALF of these mice was measured by the Sircoll Collagen Assay. (F) Lung lysates of these mice were analyzed 
by RT-PCR for MMP-12 expression. Four animals for each experiment were analyzed. Mean values ± SD are 
shown. 
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In this study, we have shown that absence of the adaptor protein FHL2 aggravates BLM-
mediated lung fibrosis. Not the final extent of fibrotic alteration was increased but its 
development at early steps was augmented and the resolution of the disease at later stages was 
retarded. Further, we have shown here for the first time that FHL2 inhibits at transcriptional 
level the expression of the pro-inflammatory ECM protein tenascin C and the DS-SIGN C-
type lectin receptor of macrophages. Consequently, a higher inflammation developed in 
FHL2-deficient lungs that were further aggravated by the inability of macrophages to be 
activated in the injured tissue due to the absence of the CD209a receptor. As a result, a 
delayed restoration of lung injury took place. This was unexpected, as FHL2 has been 
reported to positively regulate the expression of collagens type I and III, and αSMA and to 
promote the assembly of ECM proteins (Park et al. 2008; Kirfel et al. 2008; Hamidouche et 
al. 2008). Unexpected also was the observation that the inflammation state in the lung of 
control FHL2 knockout mice per se was elevated, with measurable increased amounts of the 
inflammation marker protein S100A8/A9 in lungs and sera as well.  
While the exact mechanism of BLM-induced lung fibrosis is not deciphered so far, many data 
indicate that an acute lung inflammation plays an important role (Shaw & Martin 2009; Wynn 
2011). Upon BLM application large tissue damage takes place and results in release of 
damage-associated molecular pattern molecules that initiate a non-infectious immune 
response. Neutrophils are the most abundant immune cells that infiltrate into damaged tissue 
very quickly after injury and are replaced soon by macrophages. Together with neutrophils 
macrophages remove the injured tissue debris but also play an important role in ceasing the 
inflammation and in initiating the regenerative processes by releasing cytokine- and 
chemokine-blunting proteases and other MMPs (Dean et al. 2008; Yoshizaki et al. 2008). The 
insufficient number of activated macrophages in the wounded lung tissue of FHL2-knockout 
mice probably accounts for the delayed recovery from fibrotic alterations. Depletion of 
macrophages during the recovery phase of renal fibrosis has been shown to lead to failure of 
matrix degradation and persistent scarring (Nishida & Hamaoka 2008). Also myocardial 
wound healing was impaired when macrophages have been depleted (Van Amerongen et al. 
2007). These data are in good agreement with our results showing an increase in lung fibrosis 
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upon clodronate-liposome depletion of macrophages. The absence of differences in fibrotic 
changes between WT and FHL2-knockout mice after this procedure further supports our 
hypothesis that the inability of FHL2-KO macrophages to be activated by BLM-injured tissue 
was mainly responsible for the severe progression of lung pathology in FHL2-deficient mice.  
In summary, FHL2-knockout mice are not protected against BLM-induced lung fibrosis as 
was initially expected, but develop a severe and long-lasting lung inflammation that leads to 
greater lung pathology than in WT mice. The reasons for that are probably i) the inhibitory 
function of FHL2 on transcription of the pro-inflammatory protein TNC and ii) the promoting 
function of FHL2 on transcription of the macrophage-activation receptor CD209a. As a result, 
the injured FHL2-KO lungs display high amounts of TNC and contain a reduced number 
activated and inflammation ceasing macrophages.  
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